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ABSTRACT
Effects of Chronic Electronic Vapor Exposure on Body Weight, Appetite, and Metabolism
Matthew J. Breit
Cigarette smokers weigh less than non-smokers and gain weight upon smoking cessation. Electronic
cigarettes (E-cigs) have been used as a smoking cessation tool among many, however, their effects on
metabolism, appetite, and energy balance are virtually unknown. This study compares the effects of
chronic E-cig vapor exposure on body mass, food intake, metabolism, and body composition in mice.
We hypothesized that E-cig exposure would elicit similar changes on body mass, body composition,
food intake, and metabolic and appetite-regulating markers as conventional cigarettes (i.e. 3R4F
reference cigarette). Female C57BL/6 mice were exposed to filtered room air (n=15), mainstream smoke
from 3R4F reference cigarettes (n=15), or E-cig vapor (n=15) for a total of 8-months (4 h/d, 5d/wk).
Body mass, food intake, metabolic and appetite-regulating markers, heat production, and body
composition were measured. Weight gain, fat-free mass (FFM), and fat mass were significantly elevated
in E-cig and control mice compared to 3R4F mice. Food consumption and heat production (kcal
expended/hr) was significantly increased in E-cig mice compared to control and 3R4F mice. Appetiteregulating markers (NPY, POMC, leptin, and GLP-1) were similar between all groups. Mitochondrial
uncouplers (UCP-1 and UCP-3) remained unchanged between E-cig and control groups, however, UCP1 was significantly elevated in E-cig mice compared to 3R4F mice and UCP-3 was significantly
elevated in control vs. 3R4F mice. Oxygen consumption (VO2) and carbon dioxide production (VCO2)
were also significantly elevated in E-cig and 3R4F mice compared to control mice, while respiratory
exchange ratios (RER) were unchanged. Unlike conventional cigarettes, we found that E-cig exposure
did not elicit reductions in total body or adipose mass. This suggests the effects of E-cig may not be the
same as that occurring with traditional tobacco cigarettes, or that the exposure to nicotine and/or other
chemicals in the E-cig liquid elicits a different response on appetite or feeding behavior. While E-cig
mice increased food intake, their basal metabolism was also elevated, suggesting energy dissipation
resulting in a similar net energy balance compared to control mice. Further studies are needed to
evaluate the effect that flavorings and/or the compounds produced in E-cig vapor exert on metabolism,
energy balance, and the neural regulation of appetite.
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CHAPTER 1: INTRODUCTION
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Approximately 37 million U.S. residents smoke cigarettes (Jamal et al. 2016) and over 9 million
U.S. residents have switched to electronic cigarettes (E-cigs) in hopes of cessation (Schoenborn and
Gindi 2015). An overwhelming body of evidence across multiple species suggests cigarette smoking
increases energy expenditure (Arai et al. 2001, Brees et al. 2008, Yoshida et al. 1999), decreases food
intake (Tomoda et al. 2012, Chen et al. 2005, Chen et al. 2008), and promotes weight loss (Yoshida et
al. 1999, Arai et al. 2001, Hodge et al. 1997), however, studies investigating these phenomena in regards
to E-cig vapor are sparse and inconsistent.
Nicotine, the main addictive component in tobacco, causes the anorectic and thermogenic effect
from smoking (Zoli and Picciotto 2012, Jo, Talmage and Role 2002, Tweed et al. 2012), however, the
combination of sweet aromatics, taste, and flavor, in conjunction with nicotine and other chemicals
present in E-cigs may influence appetite and body weight differently. Animal studies comparing effects
of E-cig exposure on weight gain report conflicting results, as some studies resulted in increased body
mass (Phillips et al. 2015, Russo et al. 2016), decreased body mass (El Golli et al. 2016, Golli et al.
2016, Sussan et al. 2015, McGrath-Morrow et al. 2015), or no effect on body mass (Ponzoni et al. 2015,
Cravo et al. 2016, Phillips et al. 2016, Kogel et al. 2014, Caponnetto et al. 2013, Dawkins et al. 2012).
Unlike traditional cigarettes, E-cigs appear to have varying physiological effects.
Nicotine acts on nicotinic cholinergic receptors both centrally and peripherally (McFadden,
Cornier and Tregellas 2014) within the body, which interact with numerous physiological systems.
Nicotine elicits an adrenergic catecholamine release from the adrenal medulla which act on brown
adipose tissue (BAT) and white adipose tissue (WAT) to induce lipolysis and β-oxidation of free fatty
acids (Brees et al. 2008). Nicotine binding sites have also been shown to be present in the arcuate
nucleus (ARC), an important appetite-regulating region of the hypothalamus (Pelleymounter 1997). This
suggests a direct effect of nicotine on appetite regulation via neuropeptide-Y (NPY) and pro-
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opiomelanocortin (POMC) cell populations (Huang, Xu and van den Pol 2011), thereby producing an
anorectic effect by inhibiting NPY and stimulating POMC neurons.
Propylene glycol and glycerol, the main constituents of E-cig e-liquid, are mildly sweet (Miao et
al. 2016) and may enhance the sweetening effects of ethyl maltol (Moskowitz et al. 1974, Farsalinos et
al. 2015), a sweet taste potentiator which was found in 75% of e-liquid samples tested (Miao et al.
2016). Moreover, a comprehensive random-sample market analysis of 159 e-liquids reported over 73%
of products contained diacetyl (Farsalinos et al. 2015), which has been shown to decrease glucagon-like
peptide-1 (GLP-1) production, a potent appetite suppressant, in enteroendocrine cells (McCarthy et al.
2017). E-cig use has also been shown to significantly increase appetite ratings, or perceived hunger, in
humans (Cravo et al. 2016). Finally, e-liquid can contain artificial intense sweeteners, such as sucralose
(Williams 2016) and stevia (Landau 2015), which have been shown to promote food intake through a
NPY-dependent mechanism, disrupt sleeping patterns, and increase activity patterns (Wang et al. 2016).
Together, these offer potential mechanisms for a hyperphagic response from E-cig use.
The anorectic effects of nicotine may be altered by flavoring aromatic pathways and
homeostatic, hedonic (pleasure), and motivation and reward-system regulation. The combination of
added flavorings and nicotine and their effects on food intake and body mass have not been studied
exclusively. Therefore, studies aimed at understanding the metabolic and behavioral side effects of E-cig
use are warranted. The aim of this study is to determine the metabolic and physiological effects of E-cig
vapor exposure compared to similar total time exposure to traditional cigarettes and filtered air. We
herein examine multiple appetite regulatory factors and energy metabolism markers in female C57BL/6
mice including leptin, GLP-1, POMC, NPY, uncoupling protein-1 (UCP-1), UCP-3, VO2, VCO2, and
RER. The rationale for this study was supported by matching for exposure length (4hr/day/8months) and
mass of particulate matter (PM) collected after each hour of exposure as seen in previous literature
(Ansari et al. 2016). This matching renders similar PM exposure paradigms. Using this model, we
3

expect to gain insight into the metabolic effects and appetite regulatory changes in response to E-cigs.
While the E-cig industry is over a decade old, there has been extremely limited data evaluating their
safety and efficacy. High doses of some flavor chemicals may be safe when ingested, but can be
dangerous when inhaled (Allen et al. 2016). This study evaluates the effect of long-term E-cig vapor
exposure in a mouse model to determine what, if any, effects occur on appetite regulation and obesity in
response to cappuccino flavored E-cig vapor.
Specific Aim 1: Determine the effects of long-term E-cig exposure on body mass, feed
behavior, and body composition. Our hypothesis is that E-cig vapor will decrease bodyweight, food
intake, white adipose tissue (WAT), brown adipose tissue (BAT), and FFM, in-line with 3R4F exposure.
Nicotine has been shown to decrease bodyweight, food intake, adipose tissue mass and FFM, while
increasing metabolic activity, therefore, we assume the nicotine content in E-cig and 3R4F exposures
will elicit similar physiological response.
Specific Aim 2: Determine the metabolic and molecular consequences on appetite
regulation pathways with long-term exposure to E-cig vapor. Our working hypothesis is that E-cigs
will decrease plasma leptin and glucagon-like peptide-1 (GLP-1), and hypothalamic neuropeptide-Y
(NPY) mRNA expression, while increasing, hypothalamic pro-opiomelanocortin (POMC) mRNA
expression, UCP-1 in BAT and UCP-3 in muscle. Nicotine has been show to increase POMC mRNA
expression and decrease NPY mRNA expression. Nicotine has also been shown to decrease leptin and
increase uncoupling proteins UCP-1 and UCP-3.
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CHAPTER 2: BACKGROUND AND SIGNIFICANCE
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2.1 Cigarette and E-Cigarette Usage
Worldwide, cigarette smoking and tobacco usage cause over 6 million deaths per year and is
expected to reach 8 million by 2030 (WHO 2011). Cigarette smoking in the U.S. by adults (18 and
older) has decreased from 42 million in 2013 (Jamal et al. 2014), to approximately 37 million currently
(Jamal et al. 2016). Concurrent with the decline in cigarette smoking, an alarming increase in electronic
cigarette (E-cig) use has been reported, as 9 million people currently use these products (Schoenborn
and Gindi 2015). In a meta-analysis of 28 published E-cig studies evaluating awareness, current use, and
perceived risk of E-cigs, it was found that current cigarette smokers were more likely to use E-cigs
(27.2%) than former cigarette smokers (15.7%) and non-smokers (2.5%), respectively (Xu et al. 2016).
This indicates that current cigarette smokers are more willing to find alternatives, such as E-cigs, to aid
in smoking cessation.
Tobacco use and cigarette smoking are the two leading causes of preventable death in the United
States, together causing over 480,000 deaths per year, or 1,300 deaths per day (USDHHS 2014).
Moreover, cigarette smoking costs the U.S. over $300 billion each year in lost productivity and direct
medical costs (USDHHS 2014, Xu et al. 2015). Together, with the advent of E-cig production in 2004
and increased public knowledge of the detrimental health effects of smoking tobacco products,
individuals have been switching to E-cigs in hopes of lessening their health risks from tobacco exposure.
Therefore, an in-depth understanding of their physiological effects is necessary.
2.2 Electronic Cigarettes
The American Lung Association (ALA) defines E-cigs, a popular new smoking product, as an
electronic nicotine delivery system (ENDS). E-cigs, the most common ENDS prototype, are devices that
vaporize a liquid (e-liquid) which is inhaled by the consumer, instead of using tobacco leaves used in
regular cigarettes. Since the inception of E-cigs to the global market in 2004, they have been heavily
marketed as a “safe” alternative to cigarette smoking. With over 500 brands and 8,000 flavors of e-liquid
6

on the market, the Food and Drug Administration (FDA) has only recently developed regulations for
these products following an announcement in 2016. This FDA oversight will require E-cig manufactures
to register with the FDA and submit their full ingredient lists and proprietary blends, which will be
implemented effective August 8, 2018 (ALA 2017).
E-cigs are lithium battery-powered devices that produce an aerosol through a resistive heating
coil when activated. The solution, or e-liquid, is packaged in disposable cartridges and contains
propylene glycol, glycerol, nicotine (0mg/ml-50mg/ml), various flavors, and other chemicals when
vaporized (Lam and West 2015). All E-cigs contain a battery, a body/cartridge, and an atomizer with a
heating coil. First-generation E-cig models resemble traditional cigarettes and contain low-power
batteries, while new-generation E-cigs (tank versions) contain a larger body and are capable of higher
wattage output through electronic circuits providing the ability to set the power delivery. Activation of a
first-generation E-cig, or inhalation, triggers a sensor that activates the heating element to vaporize the
e-liquid and produces an aerosol, unlike the new-generation E-cig designs which contain a manually
activated switch that activates the heating coil. New-generation devices are much more popular among
E-cig users and produce higher energy to the atomizer (Farsalinos et al. 2014a), resulting in significantly
elevated nicotine absorption, indicating that the nicotine delivery capability is correlated to the wattage
of the E-cig. Unlike first-generation E-cigs, new-generation E-cig power output is “tunable,” enabling
the user to adjust the voltage of the device, which can alter the nicotine delivery.
Multiple studies have examined the chemical composition of E-cigs (Allen et al. 2016,
Farsalinos et al. 2014a, Tierney et al. 2016, Jensen et al. 2015), effects of E-cig exposure to laboratory
animals (Ponzoni et al. 2015, El Golli et al. 2016, Golli et al. 2016, Sussan et al. 2015, Hwang et al.
2016, Ansari et al. 2016, Lo Sasso et al. 2016, Phillips et al. 2015, Phillips et al. 2016, Kogel et al. 2014,
McGrath-Morrow et al. 2015, Farsalinos et al. 2014b), and human clinical studies (Cravo et al. 2016,
Caponnetto et al. 2013, Dawkins et al. 2012, Russo et al. 2016), however, the metabolic risks attributed
7

to E-cigs are still widely unknown and require elucidation. The varying methodological protocols
(tobacco cessation, liquid injection, varying nicotine content and exposure time) makes it difficult to
cross-compare any tobacco related study involving cigarettes or E-cigs.
More than 8,000 e-liquid flavors are available on the market (Allen et al. 2016) and most are
categorized in five groups: tobacco flavored (cigarette), fruit flavors (blueberry), menthol flavors, sweet
flavors (bubble gum), and other flavors (coffee). While the majority of cigarette ads are targeted towards
adults, who are legally allowed to smoke over the age of 18, provocative industry tactics and marketing
schemes with cartoon characters and candy flavors (fruit loops and bubble gum) are clear indicators of
marketing E-cigs to youth (Farsalinos et al. 2015). In 2014, 9.2% of high school students and 2.5% of
middle school students were using cigarettes (Arrazola et al. 2015), however, marketing of E-cigs to the
younger population has proven successful, as a 900% increase in E-cig usage among high school
students was reported between 2011 and 2015, per the U.S. Surgeon General report (USDHHS 2016).
An analysis of 30 representative e-liquids available on the U.S. market revealed that almost half
of the products (13/30) contained more than 1% by weight (10mg/ml) of added chemical flavorants,
with a select few flavorants being more popular in e-liquids: vanillin, ethyl vanillin, maltol, ethyl maltol,
benzaldehyde, benzyl alcohol, ethyl butyrate, and ethyl acetate (Tierney et al. 2016). In a study of 51 eliquids, 76% (39/51) contained diacetyl (239ug/E-cig), and 23/46 of products contained 2,3pentanedione and acetoin (Allen et al. 2016). In a study of 159 e-liquids products, diacetyl and acetyl
propionyl were present in 73% of the samples, with more flavor samples containing diacetyl alone
(Farsalinos et al. 2015). Diacetyl has been shown to decrease glucagon-like peptide-1 (GLP-1) in
enteroendocrine cells (McCarthy et al. 2017), a potent appetite suppressant, which offers a potential
mechanism for hyperphagia in E-cig use.
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2.3 Nicotine Pharmacology
Nicotine, a chemical compound found in tobacco, is one of the most commonly used
psychostimulant drugs used worldwide, analogous to caffeine. Nicotine acts on nicotinic cholinergic
receptors both centrally and peripherally (McFadden et al. 2014) within the body. Acetylcholine
activates neuronal nicotinic acetylcholine receptors (nAChR), which consist of ligand-gated ion
channels and are located ubiquitously on neuronal and non-neuronal tissue and organs that regulate
energy homeostasis and regulate bodyweight (Zoli and Picciotto 2012). These receptors also respond to
nicotine, as nicotine acts on both central and peripheral nicotinic cholinergic receptors, such as high
affinity α4-β2 receptors and low-afﬁnity α7 receptors (McFadden et al. 2014).
Nicotine binding sites have been shown to be present in the arcuate nucleus (ARC), an important
appetite-regulating region of the hypothalamus (Pelleymounter 1997), suggesting a direct effect of
nicotine on appetite regulation. A specific subunit, α7nAChR, is densely expressed in the hypothalamus
and when activated, modulates appetite-related circuits (NPY/AgRP, POMC/CART neurons) within the
hypothalamus (McFadden et al. 2014, Sargent 1993) and inhibits feeding behavior. Food intake and
eating behaviors are affected by binding of nicotine to these alpha-7 nicotinic acetylcholine receptors
and may elicit the anorexigenic effects seen from smoking (McFadden et al. 2014).
Nicotine also acts peripherally on presynaptic nAChRs located on the adrenal medulla of the
kidney. Activation of these nAChRs triggers the release of both epinephrine and norepinephrine in
response to an acute smoke exposure (Sala, Nistri and Criado 2008, Zhao, Chen and Sharp 2007,
Westfall and Watts 1964), thereby increasing activity of the sympathetic nervous system. Moreover,
nicotine enhances norepinephrine turnover (Yoshida et al. 1999, Brees et al. 2008, Lupien and Bray
1988) and elevates neuronal catecholamine release from varying nicotine doses (Arqueros, Naquira and
Zunino 1978). Nicotine also has a direct effect on adipocytes by increasing lipolysis and fatty acid
breakdown, which express high-affinity nicotinic binding sites (Liu, Mizuta and Matsukura 2004).
9

Together, these data support the notion that nicotine directly effects the central nervous system (CNS)
and the activity of multiple organs involved in energy homeostasis.
Multiple studies have reported significantly reduced nicotine absorption from E-cig exposure
compared to traditional cigarette smoking (Russo et al. 2016, Allen et al. 2016, Farsalinos et al. 2014a,
Farsalinos et al. 2014b), which may cause limited weight loss and anorectic appetite effects as nicotine
is the main driver of these processes. However, the various flavors and other chemicals in the e-liquid
remain untested in relation to their impact on bodyweight and appetite. Farsalinos et. al. (2014a)
reported that serum nicotine levels were significantly less after 5, 20, 35, 50, and 65 minutes following
use of first-generation E-cigs compared to new-generation E-cigs. Moreover, after smoking a traditional
cigarette for 5 minutes (18.8 ng nicotine/ml), nicotine levels were 185% and 286% higher compared to
the new-generation and first-generation E-cigs, respectfully (Farsalinos et al. 2014a). This indicates that
nicotine delivery and absorption is significantly lower compared to traditional cigarettes.
Cigarette smoking and nicotine injections may elicit different physiological effects. Thousands
of chemicals in cigarettes may play a role in the anorectic effect of cigarettes on energy metabolism
(acetone, arsenic, carbon monoxide), however, nicotine has the most overarching and documented
effects on body weight and appetite suppression (Jo et al. 2002, Tweed et al. 2012). The interactions at
play between various artificial flavors and flavoring aromatics, in conjunction with nicotine and harmful
chemicals, such as acetone and formaldehyde, have been unidentified. It is extremely difficult to
compare cigarette smoke studies with nicotine injection data, and even more challenging to add another
variable, such as E-cig flavorings. This study will lay the rudimentary framework for future studies to
evaluate the effects of flavorings in combination with nicotine in E-cigs.
2.4 Nicotine and Appetite Regulation
An overwhelming number of studies indicate that nicotine (both I.P. injections and smoke
exposure) reduces appetite (Mangubat et al. 2012, Yoshida et al. 1999, Arai et al. 2001) and alters
10

feeding patterns (Jo et al. 2002, Zoli and Picciotto 2012). The anorectic effect of nicotine involves
multiple complex neurochemical pathways that regulate satiety and feeding patterns. As nicotine has a
high affinity for nAChRs on multiple tissues, specifically ones that regulate energy metabolism, the
physiological responses to nicotine are vast.
Appetite is regulated through multiple physiological and psychological forces, from the
distention of the stomach signaling satiety, to hormones that communicate with the brain, such as
insulin, leptin, and ghrelin. Moreover, environmental, emotional, cultural, pharmacological, and
psychological factors play major roles in influencing appetite and feeding behaviors. In addition,
numerous homeostatic circuits underlie food intake (Morton, Meek and Schwartz 2014) and feeding is
regulated by pleasant aromas (hedonic) or reward-based sensations, which override homeostatic controls
when consuming energy dense foods, increasing desire to consume palatable foods (Lutter and Nestler
2009). Sight and smell of palatable food increases dopamine release from the ventral tegmental area
(VTA), which contributes to the reward value of food (Morin et al. 2017). Activation of this pathway
results in loss of control over intake of food (Stoeckel et al. 2008). While the physiological regulation of
appetite is a major player in the regulation of appetite, and therefore, bodyweight, it is just one factor
influencing appetite, among many mentioned above. This study will examine the physiological role of
appetite regulation at the level of the hypothalamus and peripheral tissue.
The hypothalamus, a region of the forebrain, plays a key role in regulation of energy balance.
The arcuate nucleus (ARC), a specific region within the hypothalamus, is known as the main nucleus in
regards to receiving and relaying nutrient-related sensory information from the peripheral circulation
(Blouet and Schwartz 2010). Two primary “first-order” neurons within the ARC include cells expressing
the orexigenic neuropeptides neuropeptide-Y (NPY) and agouti-related peptide (AgRP), and those
expressing the anorexigenic neuropeptides pro-opiomelanocortin (POMC) and cocaine-and
amphetamine-related transcript (CART). Peripheral signals, such as leptin and ghrelin, act directly on
11

the ARC to influence the release of these four neuropeptides, which ultimately influence appetite (Park
and Ahima 2015). Raised levels of ghrelin, suggesting a starvation state and inadequate energy stores,
act to stimulate NPY/AgRP expression to increase hunger and initiate feeding, while inhibiting
POMC/CART expression. Conversely, elevated levels of leptin or insulin, such as after a meal and
indicating a fed state, act to increase expression of POMC/CART to terminate feeding, while decreasing
expression of NPY/AgRP. Nicotine binding sites have been shown to be present in the ARC
(Pelleymounter 1997), and α7nAChRs on NPY and POMC neurons are stimulated by nicotine
(McFadden et al. 2014) suggesting a direct effect of nicotine on appetite regulation.
As previously mentioned, POMC, an anorexigenic peptide, has an inhibitory effect on appetite,
while NPY, an orexigenic peptide, stimulates appetite and promotes obesity (Jo et al. 2002). POMC
exerts its appetite regulatory effects by being cleaved into multiple peptides including α-MSH, which
acts to suppress appetite. Nicotine has been shown to excite hypothalamic α7nAChRs on NPY and
POMC neurons (Huang et al. 2011), with a greater depolarization and spike frequency response from
POMC neurons, eliciting a potential mechanism through which POMC may suppress appetite (Huang et
al. 2011). Discovered in 2011, activation of POMC neurons and subsequent melanocortin-4 receptor
(MC4R) activation have been deemed the “smoking gun” in nicotine’s anorectic phenomenon, as
nicotine was shown to activate the melanocortin-4 receptors (MC4R) within the hypothalamus that
ultimately signal satiety (Mineur et al. 2011, Huang et al. 2011). However, considering these facts, the
central and peripheral underlying mechanisms attributed to the effects of nicotine’s effect on appetite
regulation remain unclear.
NPY, an orexigenic peptide, has a stimulatory effect on appetite and promotes obesity. While the
majority of cigarette smoking and nicotine injection studies on rodents report a downregulated NPY
mRNA expression within the hypothalamus (Pelleymounter et al. 1995, Jang et al. 2003, Hur et al. 2010,
Martinez de Morentin et al. 2012, Frankish et al. 1995, Li and Kane 2003) with an expected concurrent
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reduction in food intake, data regarding the effects of smoke/nicotine exposure on NPY expression are
controversial. NPY mRNA has also been reported to increase from smoke/nicotine exposure (Mineur et
al. 2011, Fornari et al. 2007, Chen et al. 2007, Li et al. 2000) or not change significantly (Chen et al.
2005), however, nicotine dosages and smoke exposure study designs may play a major role in these
discrepancies. As POMC mRNA expression and spike frequency are significantly elevated with nicotine
administration (Mineur et al. 2011, Huang et al. 2011), nicotine’s anorectic effects may be
predominately driven through this pathway instead of NPY-expressing neurons. This study will be the
first of its kind to examine the effects of E-cig exposure on POMC and NPY mRNA expression within
the hypothalamus.
Leptin, the main satiety hormone, is a 167-amino acid peptide and is synthesized and released
from white adipose tissue, while circulating leptin is directly proportional to body fat stores and reflects
the amount of long-term energy storage (Park and Ahima 2015). Leptin exerts its effects on the central
nervous system (CNS) by attaching to its receptor (OB-R) and interacts with a multifaceted neural
network to regulate food intake, and specifically, the arcuate nucleus (ARC) of the hypothalamus, which
is highly express OB-R. The ARC, containing NPY and POMC, both of which express high levels of
α7nAChRs (Erickson, Clegg and Palmiter 1996, McFadden et al. 2014), are the main sites for leptin
binding. Leptin is released from white adipose tissue in response to a meal and inhibits orexigenic
neurons that synthesize NPY, while stimulating anorexigenic neurons that synthesize POMC, resulting
in anorexigenic effects and decreased food intake (Erickson et al. 1996). OB-R distribution overlaps that
of nicotinic receptors in the hypothalamus (Jo et al. 2002), indicating a possible link between smoking
and leptin sensitivity. While some studies indicate altered leptin levels from smoking and in vivo
nicotine treatments, these effects may be secondary effects to food intake, fat lipolysis, and metabolism
(Zoli and Picciotto 2012).
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Peripheral signals, such as leptin and ghrelin, act directly on the ARC to influence the release of
NPY and POMC, which ultimately influence appetite (Park and Ahima 2015). Multiple studies have
reported cigarette smoke and nicotine injections reducing serum leptin levels (Chen et al. 2005, Chen et
al. 2008, Tomoda et al. 2012, Li and Kane 2003), with serum leptin reductions correlating in response to
nicotine dosages and WAT weight. Controversy surrounds the effect of nicotine on serum leptin levels,
as it was found that nicotine exposure did not significantly alter leptin mRNA in cultured adipocytes, or
the leptin release from adipocytes (Reseland et al. 2005), suggesting that nicotine does not directly affect
leptin release. However, in a study with 2,092 current cigarette smokers, individuals had significantly
decreased leptin compared to non-smokers, independent of BMI (Hodge et al. 1997). This may indicate
that cigarette smoking independently reduces serum leptin levels.
Glucagon-like peptide-1 (GLP-1), a 37 amino acid proglucagon-derived peptide in a family that
includes glucagon and GLP-2, is synthesized in the enteroendocrine intestinal epithelial L-cells in the
intestinal mucosal, where it responds to neuroendocrine impulses and ingested nutrients (Brubaker and
Anini 2003). GLP-1 is a known potent appetite suppressant and is secreted in response to nutrient intake
(Brubaker and Anini 2003) and acts on the GLP-1 receptors highly expressed in the hypothalamus
(McMahon and Wellman 1998) and nucleus of the solitary tract (NTS) (Hayes, Bradley and Grill 2009).
Through these actions, GLP-1 regulates body weight and food intake (Phillips et al. 2016, Turton et al.
1996). In a study of 159 e-liquids products, diacetyl and acetyl propionyl were present in 73% of the
samples, with more flavors containing only diacetyl (Farsalinos et al. 2015). Diacetyl has been shown to
decrease GLP-1 production in enteroendocrine cells (McCarthy et al. 2017), eliminating its potent
appetite suppressant effects, and which may offer a potential mechanism for increased appetite and food
intake with E-cig use.
GLP-1 receptors have also been identified on reward centers in the brain (mesolimbic reward
system, ventral tegmental area, and nucleus accumbens). Activation of GLP-1 receptors on these centers
14

reduces intake of highly-palatable foods (Alhadeff, Rupprecht and Hayes 2012). Just as palatable food
stimulates dopamine transmission in the nucleus accumbens (Norgren, Hajnal and Mungarndee 2006),
nicotine also significantly increases dopamine release (Egecioglu, Engel and Jerlhag 2013, Jo et al.
2002). Dopamine stimulates meal initiation and is associated with number of meals and meal duration
(Meguid et al. 2000). Clearly, multiple appetite regulating factors from nicotine exposure have both
appetite suppressing and stimulating effects.
Odors play a fundamental role in perception of flavor and drive for food consumption. Exposure
to various food and non-food odors increases appetite scores in humans both acutely (5 minutes) and
chronically (60 minutes). Moreover, sweet odors (chocolate) and savory odors (meat) increased appetite
to a greater extent than other aromas (Ramaekers et al. 2014). Food cues, such as the smell, taste, or
sight of appetizing food, enhances appetite and salivation in individuals (Fedoroff, Polivy and Herman
2003), while odor alone has the ability to significantly increase appetite (Yeomans 2006). This
“appetizer effect” is a form of classical conditioning and results from anticipation of a meal to optimize
digestion and absorption of soon-to-be-ingested nutrients; this is called the cephalic phase (Nederkoorn,
Smulders and Jansen 2000).
E-cigs utilize a liquid-based ingredient mixture as a nicotine delivery vehicle, called e-liquid. Eliquid contains propylene glycol, glycerol, water, and nicotine, which can be combined with various
flavors. Without FDA regulations in effect until 2018, e-liquid may contain numerous unknown and
unlabeled ingredients. As millions of individuals are switching from cigarettes to E-cigs in hope of
cessation, the post-cessation weight gain may be augmented due to the flavoring profiles in e-liquid
(Caponnetto et al. 2013, Russo et al. 2016, Cravo et al. 2016).
The AHA defines low-calorie sweeteners, artificial sweeteners, and non-caloric sweeteners as
non-nutritive sweeteners (NNSs), since they offer no nutritional benefits and offer low or zero calories
(AHA 2014). NNSs are derived from plants, herbs, or sugar, and have a greater intensity of sweetness
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compared to sugar, therefore, low concentrations can be used to sweeten foods and beverages (Clinic
2013). The FDA has approved the label of “Generally Recognized as Safe” to five NNSs (aspartame,
acesulfame-K, neotame, saccharin, and sucralose), which are hundreds of times sweeter than sucrose
and are used in several products worldwide (AHA 2014). While these products are approved by the
FDA, an ongoing debate persists over their effect on body weight, appetite regulation, and energy
metabolism. Interestingly, NNS consumption compared to sucrose, glucose, or control groups, has been
shown to scientifically increase body weight without increasing caloric intake (Swithers and Davidson
2008, Feijo et al. 2013, Foletto et al. 2016), suggesting an altered metabolism.
E-cigs often contain numerous ingredients that improve taste and stability, such as sweeteners,
flavorants, colorants, dextrins, starches, cellulose, carbohydrates, and polyols. Interestingly, artificial
sweeteners, such as sucralose (Williams 2016) and stevia (Landau 2015) are often used in e-liquid to
provide sweet flavors. Sucralose consumption increases dopamine release at similar levels compared to
sucrose consumption (de Araujo et al. 2008), and indicates reinforcement factors for sweetness exist
from sweet flavor alone. It was discovered that nicotine enhances the response for caloric sugar intake
reward, primarily driven by sweetness, rather than caloric content of the food (Rupprecht et al. 2016).
Nicotine has been shown to increase the response for a saccharin and sucrose fluid reward, however, not
for enhancement for chow food reward sweetened with sucrose or saccharin. A wide array of
multisensory reward systems are at play, such as taste perception and post-prandial awards, and
moreover, visual and olfactory anticipatory cues play a major role in the full effect of an “adequate
meal” (de Araujo et al. 2008). Artificial sweeteners also activate different taste pathways in the brain
from sucrose, and the brain distinguishes sucrose (calorie-dense) from intense sweeteners (non-caloric)
when the conscious mind does not (Frank et al. 2008). This may have major implications as NNSs are
used for sugar substitution, and it may subconsciously increase added sugar intake. If E-cigs employ the
use of NNSs to sweeten their e-liquid to improve the palatability, taste, and mouthfeel of vaping, the
16

possible ingestion of the e-liquid may influence appetite in a completely different way compared to
inhalation.
Multiple studies have examined the effects of E-cig exposure on anthropometric measures
(Ponzoni et al. 2015, El Golli et al. 2016, Sussan et al. 2015, Cravo et al. 2016, Russo et al. 2016,
Caponnetto et al. 2013, Kogel et al. 2014, Phillips et al. 2016, Phillips et al. 2015, McGrath-Morrow et
al. 2015). However, there is controversy between the relationship, as one chronic, 7-month exposure of
E-cig vapor increased bodyweight over control animals (Phillips et al. 2015), some E-cig studies saw a
decrease in body weight (Sussan et al. 2015, El Golli et al. 2016, McGrath-Morrow et al. 2015), and
others saw no effect (Ponzoni et al. 2015, Cravo et al. 2016, Russo et al. 2016, Caponnetto et al. 2013,
Phillips et al. 2016, Kogel et al. 2014). Two studies using similar nicotine content as our study exposed
mice to E-cigs and traditional cigarettes, (Kogel et al. 2014, Phillips et al. 2016), however, only one
study resulted in weight loss. Interestingly, a third study displayed the opposite effect, reporting an
increase in weight from E-cig exposure (Phillips et al. 2015). The added flavorings in the E-cig may
overpower nicotine’s lipolytic and anorexigenic effects.
McGrath-Morrow et al. (2015) exposed neonatal mice to E-cig vapor containing 0% nicotine or
1.8% nicotine and both groups experienced weight loss. This suggests either nicotine is not the sole
source of weight loss in E-cig vapor, or a prepubertal stunted growth effect occurred with exposure to Ecig vapor. The same controversy surrounds E-cig use and food intake, as one study reported decreased
food intake (El Golli et al. 2016), four reported no change (Ponzoni et al. 2015, El Golli et al. 2016,
Kogel et al. 2014, Phillips et al. 2016), and one reported increased appetite in humans (Cravo et al.
2016). The combination of nicotine and various other chemicals in the E-cig liquid may elicit a differing
response than cigarette or nicotine injection alone.
While there is clear evidence that cigarette smoking suppresses appetite through the actions of
nicotine-mediated pathways, it is unclear in regards to E-cig vapor and inhalation of nicotine and other
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aromatics. This new product which provides added flavors and aromatics to nicotine delivery has the
potential to interfere with appetite regulating pathways. E-cigs introduce novel complications to the
regulation of appetite, as the effects of added flavors and nicotine have not been studied in such a
context. A variety of conscious and subconscious factors play into appetite and therefore, body weight
effects, such as altered feeding patterns, addiction, taste profile, microflora, sleep patterns, stress,
anxiety, mouthfeel, flavor, smell, sight, and hormonal responses within the body. Therefore, a thorough
investigation into the effects of added flavors and nicotine must be conducted.
2.5 Nicotine and Obesity, Adiposity, and Body Composition
In humans, obesity is thought of as an energy imbalance between consumption of calories and
calories expended. However, the etiology of obesity contains multiple factors and cannot be explained
solely by the hypothesis of calories-in verses calories-out. For example, obesity has been attributed to
viral infections (Dhurandhar et al. 2002) and bacterial infections (Turnbaugh et al. 2008), termed
infectobesity, rather than an imbalance between caloric intake and energy expenditure. The AD-36
adenovirus has been reported to increase body fat in monkeys (Dhurandhar et al. 2002) and lean, germfree mice given a microbiota transplantation from mice with diet-induced obesity (DIO) gained
significantly more adipose tissue than transplants from lean donors (Turnbaugh et al. 2008). Obesity has
also been attributed to an altered energy metabolism (Breslow et al. 1999), as ob/ob mice (leptin
deficient) gain significantly more weight due to decreased energy metabolism and lack of satiation.
Together, these data provide insight to the complexities of obesity and the various factors that contribute
to it.
Cigarette smoking is the leading preventable cause of death in the U.S. (USDHHS 2014),
followed closely by obesity-related chronic diseases. The obesity rate for U.S. adults is now over 37%
(CDC 2016) which contributes to heart disease, stroke, and type II diabetes. To compound these
diseases, an obese smoker has a lifespan 13 years less than that of a normal weight nonsmoker (Chiolero
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et al. 2008). Moreover, cigarette cessation has been attributed to a 14% rise in US obesity rates
(Courtemanche, Tchernis and Ukert 2016) and alternative nicotine therapies, such as E-cigs are
currently being used to help mitigate these effects. Clearly, smoking cessation and weight management
are two primary ways to assist in disease prevention and healthy aging.
An overwhelming body of scientific evidence and longitudinal studies suggest that cigarette
smokers weigh less than non-smokers (Audrain-McGovern and Benowitz 2011, Albanes et al. 1987) and
gain significantly more weight upon cessation (Mozaffarian et al. 2011), which makes people reluctant
to quit (Chiolero et al. 2008) and intentionally use cigarette smoking as an effective weight loss tool
(Potter et al. 2004). The Second National Health and Nutrition Examination Survey (NHANES II)
examined the relationship between tobacco use and bodyweight of 12,103 individuals (Albanes et al.
1987) and found a direct correlation between cigarette smoking and a lower bodyweight. Moreover, a
10-year study examining the body mass index (BMI) and mortality of over 9,000 cigarette smokers
resulted in smokers exhibiting a significantly reduced BMI compared to nonsmokers, and gained weight
exceeding that of non-smoker baseline levels (Audrain-McGovern and Benowitz 2011) upon smoking
cessation. Experimentally, both acute (Sanigorski et al. 2002, Frankish et al. 1995) and chronic (Sztalryd
et al. 1996, Mangubat et al. 2012, Yoshida et al. 1999, Arai et al. 2001, Rasmussen 1998) moderate
nicotine dose injections (>1.0mg/kg) also elicit this anorectic bodyweight response, apart from effects of
cigarette smoke. However, acute, low dose nicotine injections (<1.0mg/day) have no effect on body
weight (Lupien and Bray 1988, Brees et al. 2008). This provides compelling evidence that nicotine in
moderate to high doses has a potent anorectic effect and reduces bodyweight, unlike low doses.
Catecholamines released in response to nicotine binding to the adrenal medulla act on β3adrenergic receptors on brown adipose tissue (BAT) and white adipose tissue (WAT) to induce lipolysis
and β-oxidation of free fatty acids (Brees et al. 2008). In cultured adipocytes, nicotine increases lipolysis
(An et al. 2007), while inhibiting lipoprotein lipase (LPL) activity (Chajekshaul et al. 1994) and fatty
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acid synthesis (An et al. 2007). Nicotine decreases LPL by 30% and it’s suggested that nicotine diverts
fat storage from the adipose tissue to be utilized by the muscle as free fatty acids (FFA) (Sztalryd et al.
1996). In a study evaluating the effect of nicotine on body composition in mice, it was found that 42
days of nicotine injections (1.5 mg/kg/day) significantly decreased lean mass while fed a high-fat diet,
however, no effect was seen in mice fed standard chow (Mangubat et al. 2012). This may be due to
increased fat deposition in the muscle of mice fed a high-fat diet.
While it has been extensively proven that nicotine’s effect on nicotine-mediated pathways is the
main driver of the anorectic response seen from cigarette smoking, it is unclear what effects nicotine
will elicit when combined with various flavors and aromatics in the e-liquid, rather than the thousands of
other chemicals in traditional cigarettes. While this study cannot extrapolate which added flavors or
aromatic interactions are causing a weight/appetite response, it will be able to answer what physiological
repercussions occur from inhalation of nicotine and added flavors, combined, from E-cig exposure.
2.6 Nicotine and Energy Metabolism and Uncoupling Proteins
Oxidative phosphorylation, the synthesis of mitochondrial adenosine triphosphate (ATP) from
adenosine diphosphate (ADP) substrate, is driven by the flow of electrons from NADH to oxygen. In
1961, Peter Mitchell demonstrated that oxidation is coupled to the electron transport chain by proton
pumping across the mitochondrial membrane, which creates a proton motive force for protons across the
mitochondrial inner membrane (Mitchell 1961). This proton motive force pushes protons through ATP
synthase and couples proton transport to phosphorylation of ADP (Nicholls and Rial 1984). However,
when ADP phosphorylation is inhibited, mitochondria still consume some oxygen, which means
coupling of respiration to ATP synthesis is defective. Inner mitochondrial membrane leaks may impair
coupling of oxidative phosphorylation, therefore, an uncoupling mechanism has been proposed.
Uncoupling protein (UCP) homologues are evolutionarily related mitochondrial transporters
(Ricquier and Bouillaud 2000). Uncoupling proteins activate substrate oxidation and dissipate energy as
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heat instead of storing it as ATP. These are immensely important for energy balance, weight
maintenance, and energy metabolism. UCP1 is exclusively found in brown adipose tissue (BAT) and is
involved in cold-induced thermogenesis, causes proton leakage, and decreases mitochondrial electron
chain efficiency, leading to heat production (Azzu and Brand 2010). UCP1 is a mitochondrial proton
carrier and shifts the energy metabolism from producing ATP to releasing heat, which contributes to
increased energy expenditure in smokers (Chen et al. 2007, Klesges et al. 1989).
Uncoupling protein-3 (UCP3) is primarily found in skeletal muscle. UCP3 is involved in
mitochondrial fatty acid oxidation and the prevention of reactive oxygen species (ROS)-induced
oxidative damage and lipid hyperoxide (LOOH) oxidative stress within the mitochondria (Cioffi et al.
2009) . Unlike UCP1, UCP3 is a mild-uncoupler and is involved in energy metabolism through
mitochondrial fatty acid oxidation and mitochondrial uncoupling at the level of the muscle. Through
mild uncoupling and protection from ROS/LOOH-induced oxidative damage, UCP3 offers protection
against obesity and type 2 diabetes mellitus (T2DM).
Nicotine acts peripherally on WAT and BAT (Yoshida et al. 1999, Klesges et al. 1989) and
decreases the mass of each tissue (Chen et al. 2005, Chen et al. 2007, Yoshida et al. 1999). BAT is the
principal mediator of adaptive thermogenesis in rodents and is activated through β3-adrenergic
receptors. Nicotine and cigarette smoking stimulates release of catecholamines (NE, EPI) from the
adrenal medulla (Sala et al. 2008), which act on β3-adrenergic receptors on BAT and WAT to induce
lipolysis and β-oxidation of free fatty acids (Brees et al. 2008). Studies show nicotine increases UCP1
mRNA and protein expression in BAT and WAT (Arai et al. 2001, Yoshida et al. 1999), while others
show a decrease in BAT UCP1 expression, but increased UCP3 expression (Chen et al. 2005, Chen et al.
2008).
Oxygen consumption (VO2) is defined as the amount of O2 consumed and used by the body
through the process of aerobic metabolism. As lungs take up O2, the O2 is used to produce ATP in the
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mitochondria of cells. Therefore, measuring VO2 is a well-documented marker to calculate the total
energy expenditure of a subject. Similarly, carbon dioxide production (VCO2) is defined as the amount
of carbon dioxide that an individual exhales after transport through the body, making it an excellent
marker for cellular metabolic processes (Marvyn et al. 2015). As CO2 is a by-product of cellular
respiration, measuring VCO2 is a reliable marker for metabolism. These two values are useful for
measuring the respiratory exchange ratio (RER), which is the ratio of VCO2/VO2. RER estimates the
source of fuel substrates being used to produce ATP by cells at basal and low-intensity exercise periods
(Marvyn et al. 2015). An RER = 1.0 suggest the carbohydrates (CHO) are the primary source of energy,
while RER = 0.7 suggests fats are being used for energy production.
VO2 (ml/min) = HR x SV x A-vO2difference
VCO2 (ml/min) = VE x (FeCO2-FiCO2)
RER = VCO2/VO2
Cigarette smoking and I.P. nicotine administration have been reported to elevate total body
oxygen consumption, or VO2, by 6% and 9% in canines, respectively (Ilebekk, Miller and Mjos 1975).
However, when β-pyridylcarbinol was administered to inhibit lipolysis, total body oxygen consumption
was unaltered between groups. This suggests that an increased mobilization and consumption of freefatty acids (FFAs) was the likely mediator of the rise in total body oxygen consumption. As nicotine has
been reported to increase lipolysis and fatty acid breakdown (Liu et al. 2004), an increased FFA
consumption due to nicotine exposure is likely. RER values in habitual smokers (varying from light to
heavy smokers) have been reported to be similar to non-smokers during a maximal treadmill
cardiovascular test (Bruce treadmill protocol) and range between 1.0-1.2 (Suminski et al. 2009),
however, smokers at rest may have a significantly lower RER, suggesting increased FFA metabolism.
This will be the first study to examine the effects of E-cig exposure on VCO2, VO2, and RER.
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Total daily expenditure is calculated as the sum of resting metabolic rate, thermic effect of food,
and physical activity, while resting metabolic rate (RMR) accounts for nearly 70% of total energy
expenditure in humans. A small change in RMR could drastically alter energy balance and weight status.
Heavy smoking increased 24-hr energy expenditure by 10% in humans (Hofstetter et al. 1986), resulting
in 200kcals/24 hrs, which, without a change in food intake, would result in a 10 kg weight loss in one
year. Nicotine increases thermogenesis by increasing lipolysis in adipose tissue via inhibition of
lipoprotein lipase (LPL) activity and decrease of triglyceride (TG) storage, which in turn reduces overall
net adipose storage (Jo et al. 2002). Moreover, nicotinic receptor activation by nicotine increases UCP1
expression in both WAT and BAT (Arai et al. 2001). Taken together, this data indicates nicotine has a
direct lipolytic effect on adipose tissue and while increasing metabolism, results in weight loss.
While there is clear evidence that cigarette smoking has some effect on energy metabolism and
increases thermogenesis through the actions of nicotine-mediated pathways, it is unclear in regards to Ecig vapor and inhalation of nicotine and other aromatics. To our knowledge, no other study has
examined the effects of chronic E-cig exposure on uncoupling proteins and resting metabolic rate.
2.7 Summary of Background and Significance
This research is important for three main reasons. First, while there has been substantial research
on nicotine or added flavors on appetite regulation and body weight, the combinative effects of added
flavors and nicotine in E-cig vapor on appetite, body composition, and metabolism are virtually
unknown. This study is the first of its kind to evaluate the effects of E-cigs on energy metabolism and
neuroendocrine peptides. While E-cigs are marketed as a safe alternative to cigarette smoking, they still
produce formaldehyde, a known carcinogen. While nicotine has been proven to induce weight loss, the
added chemicals and ingredients in E-cigs, such as the various flavors, have unknown effects on our
physiology and appetite in combination with nicotine. Second, a review of the literature involving
nicotine and metabolism demonstrated multiple inconsistencies regarding the appetite-regulatory factors
23

at play with nicotine administration, specifically, leptin, ghrelin, NPY, and POMC (Jang et al. 2003,
Frankish et al. 1995).The majority of studies examining the metabolic effects of cigarette smoke and
nicotine injections are acute. With this chronic, 8-month study, we will shed light on long-term effects
of these potentially harmful consumer products. Third, one of the most serious public health issues is
obesity and its relation to chronic diseases. We have chosen to study the effects of nicotine on weight
loss because understanding the etiology of obesity, weight loss, and subsequent weight gain with
nicotine cessation, will increase our understanding of this health epidemic and may help ameliorate such
a response.
E-cigs are being marketed as a tobacco cessation tool, and while traditional cigarette smoking
induces weight loss by inhibiting hunger and increasing thermogenesis, it remains unclear if the same
holds true for E-cigs. Nicotine alters NPY and POMC mRNA expression which results in hypophagia,
however nothing is known about the effects from E-cig exposure. Nicotine also increases thermogenesis
and lipolysis by acting on nAChRs within the CNS, however, no research has been done on E-cigs. Ecigs contain both nicotine and added flavors, which may have a dissimilar physiological effect of
traditional cigarettes. As weight gain is seen in individuals who quit tobacco cigarettes, if they transition
to E-cigs, the weight gain may be more pronounced due to added flavorings altering appetite and
subsequent caloric intake. Consequently, there is a need to investigate the role of E-cigs in the role of
energy metabolism and appetite regulation.
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ABSTRACT
Nicotine and cigarette smoking promotes weight loss and suppresses appetite. Since 2007, the
use of electronic cigarettes (E-cig) has increased dramatically in the US, however only a few studies
have examined the long-term consequences of e-vapor, particularly in the context of appetite
regulation/weight management. This study compares the effects of chronic E-cig vapor exposure on
food intake, body weight, and body composition in mice. We hypothesized that E-cigs would elicit
similar changes on body mass, adiposity, and food intake as conventional cigarettes (i.e. 3R4F reference
cigarette). Female C57BL/6 mice were exposed to filtered room air (n=15), mainstream smoke from
3R4F reference cigarette (n=15), or E-cig vapor (n=15) for a total of 8 months. Assessments of body
mass, food intake, body composition, metabolism, and appetite-regulating peptides following daily
exposure (4 h/d, 5d/wk, 8/mo) are shown. Food and water were administered ad libitum. E-cig, control,
and 3R4F mice increased body mass by 52%, 47%, and 38%, respectively, over 8 months. E-cig mice
had 14% higher body mass compared to 3R4F mice (p<0.01). E-cig mice had significantly elevated
mean fat-free mass (FFM, 18.2±0.2g) and mean fat mass (3.8±0.3g) compared to 3R4F (17.0±0.2g and
2.99±0.2g) mice (p<0.01). Body mass, FFM, and fat mass were similar between E-cig and control mice.
Food consumption was significantly increased in E-cig mice (50.7±2.3g) compared to 3R4F (42.8±0.8g)
and control mice (45.2±1.0g, p<0.05) respectively, over a 15-day food trial, however, NPY, POMC,
leptin, and GLP-1 were similar between all groups. Heat production (kcal/hr) during light-phase was
significantly greater in E-cig mice by 15% and 16% compared to 3R4F and control groups, respectively
(p<0.01). Heat during dark-phase also tended to be greater in E-cig mice by 7% and 8% compared to
3R4F and control, respectively, but did not reach significance (p=0.18). Light-phase oxygen
consumption (VO2) was also significantly increased in E-cig (16%) and 3R4F (12%) mice compared to
control mice (p<0.05), however, it was unchanged during dark-phase. Light-phase carbon dioxide
production (VCO2) was significantly higher in E-cig mice (17%, p<0.05) and trended towards
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significance in 3R4F exposed mice (p=0.06) compared to control mice. Dark-phase VCO2 was not
different among groups (p>0.05). Respiratory exchange ratio (RER) was not different among groups
during either the light- or dark-phase. E-cig BAT UCP-1 expression was significantly increased
compared to 3R4F mice (p<0.05) and muscle UCP-3 was significantly increased in control mice
compared to 3R4F mice (p<0.05). Unlike conventional cigarettes, we found that E-cig exposure did not
elicit reductions in total body or fat mass. This suggests the effects of E-cig may not be the same as that
occurring with traditional tobacco cigarettes, or that the exposure to nicotine and/or other chemicals in
the E-cig liquid elicits a different response on appetite or feeding behavior. While E-cig mice increased
food intake, their heat production was also elevated, suggesting energy dissipation and increased
metabolism resulting in a similar net energy balance compared to control mice. Further studies are
needed to evaluate the effect that flavorings and/or the compounds produced in E-cig vapor exert on
metabolism, energy balance, and the neural regulation of appetite.

Abbreviations
E-cig - electronic Cigarette
ARC- arcuate nucleus
NPY – neuropeptide-y
POMC – pro-opiomelanocortin
CART – cocaine and amphetamine-related transcript
AgRP – agouti-related peptide
OB-R – leptin receptor
GnWAT – gonadal white adipose tissue
RpWAT – retroperitoneal white adipose tissue
BAT – brown adipose tissue
WAT – white adipose tissue
UCP – uncoupling protein
3R4F - cigarette
CLAMS – comprehensive lab animal monitoring system
GA – gastrocnemius
FFM – fat-free mass
RER – respiratory exchange ratio
TBST – tris-buffered saline with Tween 20
GLP-1 – glucagon-like peptide-1
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INTRODUCTION
Approximately 37% of the U.S. population is obese (CDC 2016) and cigarette cessation has been
attributed to a 14% rise in these rates (Courtemanche et al. 2016). Electronic cigarettes (E-cigs) are
nicotine delivery devices, currently used by more than over 9 million U.S. residents in hopes of smoking
cessation (Schoenborn and Gindi 2015). An overwhelming body of evidence across multiple species
suggests cigarette smoking increases energy expenditure (Arai et al. 2001, Brees et al. 2008, Yoshida et
al. 1999), decreases food intake (Tomoda et al. 2012, Chen et al. 2005, Chen et al. 2008), and promotes
weight loss (Yoshida et al. 1999, Arai et al. 2001, Hodge et al. 1997), however, studies investigating
these phenomena in regards to E-cig vapor are sparse and inconsistent.
E-cigs utilize a liquid-based ingredient mixture as a nicotine delivery vehicle, called e-liquid. Eliquid contains propylene glycol, glycerol, water, and nicotine, which can be combined with various
flavors. Nicotine acts on nicotinic cholinergic receptors both centrally and peripherally (McFadden et al.
2014) within the body. Nicotine binding sites have been shown to be present in the arcuate nucleus
(ARC), an important appetite-regulating region of the hypothalamus (Pelleymounter 1997), suggesting a
direct effect of nicotine on appetite regulation via neuropeptide-Y (NPY) and pro-opiomelanocortin
(POMC) neurons (Huang et al. 2011). Moreover, nicotine elicits catecholamine release from the adrenal
medulla which act on brown adipose tissue (BAT) and white adipose tissue (WAT) to induce lipolysis
and β-oxidation of free fatty acids (Brees et al. 2008).
Propylene glycol and glycerol, the main constituents of E-cig e-liquid, are mildly sweet (Miao et
al. 2016) and may enhance the sweetening effects of ethyl maltol (Farsalinos et al. 2015, Moskowitz et
al. 1974), a sweet taste potentiator which was found in 75% of e-liquid tested (Miao et al. 2016).
Moreover, a comprehensive random-sample market analysis of 159 e-liquids found over 73% of
products contained diacetyl (Farsalinos et al. 2015), which has been shown to decrease glucagon-like
peptide-1 (GLP-1) in enteroendocrine cells (McCarthy et al. 2017), a potent appetite suppressant.
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Together, these offer a potential mechanism for hyperphagia with E-cig use. E-cig use has also been
shown to significantly increase appetite ratings, or perceived hunger, in humans (Cravo et al. 2016).
Finally, e-liquid can contain artificial intense sweeteners, such as sucralose (Williams 2016) and stevia
(Landau 2015), which have been shown to promote food intake through a NPY-dependent mechanism,
disrupt sleeping patterns, and increase activity patterns (Wang et al. 2016). Together, these offer a
potential mechanism for diet-induced obesity through an increased hyperphagic response following
chronic E-cig use.
Food cues, such as the smell, taste, or sight of food enhances appetite and salivation in
individuals (Fedoroff et al. 2003), while sweet odor has a potent appetite stimulating effect (Yeomans
2006). A form of classical conditioning, this “appetizer effect” results from anticipation of a meal to
optimize digestion and absorption of soon-to-be-ingested nutrients, also known as the cephalic phase
(Nederkoorn et al. 2000). While the effects of nicotine on appetite and bodyweight are robust, the
combination of the inhalation of nicotine and sweet aromatics (e-liquid) is largely unknown. As millions
of individuals are switching from cigarettes to E-cigs in hope of cessation, the post-cessation weight
gain may be augmented due to the flavoring profiles in e-liquid (Caponnetto et al. 2013, Russo et al.
2016, Cravo et al. 2016).
Literature surrounding E-cig use on body weight and food intake are controversial, as some
studies report increased weight gain (Phillips et al. 2015, Russo et al. 2016), decreased weight gain (El
Golli et al. 2016, Golli et al. 2016, Sussan et al. 2015, McGrath-Morrow et al. 2015), or no weight gain
(Ponzoni et al. 2015, Cravo et al. 2016, Phillips et al. 2016, Kogel et al. 2014, Caponnetto et al. 2013,
Dawkins et al. 2012), without investigating the mechanistic cause. The anorectic effects of nicotine may
be altered by flavoring aromatic pathways and homeostatic, hedonic, and reward-system regulation.
Therefore, studies aimed at understanding the metabolic and behavioral side effects of E-cig use are
warranted.
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The purpose of this study was to determine the metabolic and physiological effects of chronic Ecig vapor exposure. We hypothesize that E-cig exposed mice will exhibit decreased food intake,
increased lipolysis, and increased cage activity, resulting in a decreased body mass compared to litter
mate controls.
MATERIALS AND METHODS
All experiments were approved by and conducted in accordance with the guidelines of the West
Virginia University Institutional Animal Care and Use Committee.
Animals
Forty-five C57BL/6 female mice bred in pathogen-free environments were obtained from
Jackson Laboratory, Bar Harbor, Maine, USA (Stock #000664, respectively) and were 10 weeks old
upon arrival (Table 1). Mice were allowed a one week acclimatization period and randomly divided into
three treatment groups (n=15/group) consisting of a conventional reference cigarette (3R4F, exposed to
mainstream smoke), E-cig (exposed to mainstream vapor), or control (exposed to filtered air). Mice
were 13-14 weeks old at exposure initiation, followed by 8 months of exposure (ending at ~12 months
of age). Mice were group housed by treatment (4-5 mice/cage), kept on a 12-h light/dark cycle, 22 ± 4°C
temperature, 39 ± 6% relative humidity, and provided an ad libitum tap water and standard chow diet
(18% fat, 24% protein, 58% CHO; Teklad Diet, Madison, WI), unless otherwise noted. Cob bedding
was changed on a bi-weekly basis. Mice were monitored daily for health, mortality, and morbidity.
3R4F Reference Cigarette, E-Cigarette, Smoke/Vapor Generation, and Exposure
Mice were exposed as single respective treatment groups (i.e. E-cig, 3R4F cigarette, or filtered
air) at the same time (n=15/group) using identical 15.1 L whole body exposure chambers. E-cig vapor
and tobacco smoke was gradually introduced during the first 8 weeks, after which point the mice were
consistently exposed to four 1-hour exposure blocks, with each exposure separated by 30 minute
intervals of fresh air breaks, resulting in an intermittent exposure pattern for a total exposure time of 4
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hours each day (occurring over 6-hour window of time each day). This daily regime was applied 5
days/week for a total of 8 months.
The 3rd generation, tank-style, E-cig device was purchased online (eGrip™OLED, Joyetch,
ShenZhen, China, www.joyetch.com). The E-cig device was activated by a custom-made electronically
controlled cradle (courtesy of Dr. Powsiri Klinkhachorn, Dept. of Electrical Engineering, West Virginia
University, Morgantown, WV, USA) that allowed precise and reliable control of the frequency and
duration of E-cig activation. The E-cig was activated every 99 seconds for a 5-second duration (3839/puffs/hour), with voltage set at 4.8 V. E-liquid was purchased from Joyetech and a local vendor
(VaporHut, Morgantown, West Virginia, USA), containing 50% vegetable glycerin, 50% propylene
glycol, cappuccino flavoring extract, and 18 mg/ml nicotine. Estimated nicotine concentrations of E-cig
exposure was 27mg nicotine/day (1.5 ml e-liquid x 18mg nicotine/ml).
3R4F standard reference cigarettes (9.5mg tar, 0.73mg nicotine) were purchased from the
University of Kentucky, Center for Tobacco Reference Products (http://www.ca.eky.edu/refcig), were
stored in 4°C for the duration of the study and set in room air one week prior to use. One cigarette was
loaded and lit on the ventilator inlet every 10 minutes, resulting in 6 cigarettes/hr (24 cigarettes/day of
the 4-hr exposure paradigm).
Vapor, smoke, and air were generated and delivered independently, but identically, to each
respective group polypropylene exposure chamber. Rodent ventilators (Harvard Apparatus Dual Phase
Control Respirator, Model 55-0715, South Natick, Massachusetts, USA), with 55ml tidal puff volume
were used. Control mice received filtered air (Whatman, GE Healthcare Life Sciences, Carbon Cap 150)
from a central compressed air line. Each chamber had a bias flow of ~3 l/min and all exposures occur
simultaneously each day.
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Measurements
Prior to smoke/vapor exposure initiation, a series of non-invasive, ex and in-vivo measurements
were conducted. These included: EchoMRI body composition analysis and metabolic assessment using a
comprehensive lab animal monitoring system (CLAMS) as later described. Midpoint measurements for
non-invasive assessments were conducted at months 2 and 5 of treatment.
Body Weight and Food Intake
Animal body mass was measured twice each week between 0700 and 0800 to monitor growth
and general health. Individual food intake was measured at week 3, 7, 19, 23, and 29 over a three-day
span (Friday-Monday, during periods of no exposures) in mice individually caged. Total caloric intake
(energy density) was calculated as grams of chow eaten x 3.1 (as chow was 3.1kcal/g). The 15-day food
intake was calculated by the summation of total calories consumed during food measurement trials at
weeks 3, 7, 19, 23, and 29. Weekly, group food intake was also measured during the last month of
exposure and reported as g/week.
Body Composition, Adipose, and Muscle Tissue
Body fat, fat free mass (FFM), free water (FW), and total body water (TBW) were measured
with an EchoMRI small animal body composition analyzer (Model 100H; Houston, TX,
www.echomri.com) at month 0, 2, 5 and 8. On a separate day from the laboratory pre-testing, but prior
to the first exposure, animals entered the body composition analyzer for determination of body fat, FFM,
FW, and TBW. This procedure was non-invasive, does not require anesthesia, and correlates strongly
with DEXA measurements (Galgani, Smith and Ravussin 2011). Three measurements were conducted
on each animal. Measurements were conducted between 0600 and 1000 in a basal state, at least 24 hours
post last exposure.
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Tissue Collection and Processing
Upon completion of the 8-month exposures, animals were sacrificed after an 8-hour caloric fast
and 24-hours post final any exposure. Animals were anesthetized (ketamine/xylazine intraparietal (IP)
dose) and administered a paralytic agent (IP, pancuronium bromide, 0.8 mg/kg). Major organs were
carefully dissected, weighed, flash frozen, and stored at -80°C for later analysis. Blood was collected
from a heart puncture and allowed to clot at room temperature for 30 minutes, followed by
centrifugation (2000g for 10 minutes at 4°C). Serum was collected and flash frozen in liquid nitrogen,
and stored at -80°C for subsequent determination of serum leptin (#90030, Crystal Chem Inc. Downers
Grove, IL, USA) and GLP-1 (#EZGLP1T-36K, Millipore, St. Charles, MO, USA) by ELISA assay.
Urine was collected at month 5 immediately after exposure (hour 1, 2, and 3 post exposure) for
determination of urinary cotinine (CALBIOTECH, El Cajon, California, USA) by ELISA assay. No
sample dilutions were necessary. All three ELISA kits was used per the manufacturer’s instructions.
Leptin, GLP-1, and cotinine were measured on one assay kit. Immediately following blood collection,
animals were decapitated, the brain was removed on ice, and the hypothalamus was excised, flash
frozen, and stored at -80°C for determination of total mRNA concentrations of neuropeptide-y (NPY)
and pro-opiomelanocortin (POMC) using reverse transcription polymerase chain reaction (rt-PCR).
White adipose tissue (retroperitoneal (RpWAT) and gonadal (GnWAT), interscapular brown adipose
tissue (BAT) and gastrocnemius (GA) muscle were dissected, weighed, snap frozen, and stored at -80°C
for later determination of total protein expression of UCP-1 and UCP-3 using western blotting
technique.
Western blot analysis
Basal protein expression of BAT UCP-1 and GA UCP-3 were analyzed using western blot. BAT
samples were homogenized in Lysis Buffer (5.96 g HEPES (50 mM), 4.38 g NaCl (150 mM), 50 mL
glycerol (10%), 5 mL Triton X-100 (1%)), pH of 7.5 with an EDTA-free protease inhibitor tablet
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(cOmplete Mini, 1 tab/10ml). Muscle GA samples were homogenized in Tris-buffered saline (50mM
tris/HCl, 150mM NaCl, 0.5% Triton X-100), a protease inhibitor tablet, and H2O. After
homogenization, BAT and GA samples were incubated by gentle rotation for 40 minutes at 4°C,
followed by centrifugation (16,100g, 20 min, at 4°C). The supernatants were collected and stored at
− 80 °C for later determination of UCP-1 and UCP-3 protein content by western blot. Total protein was
measured by Bradford assay (#23236 Pierce Coomassie Plus Protein Assay Kit, Thermo Scientific,
Rockford, IL).
Total protein for UCP-1 (60µg) and UCP-3 (60µg) were reduced, denatured, electrophoresed
with a 4-12% SDS-PAGE (NuPAGE Novex 4-12% Tris-Acetate Midi Gel, Invitrogen, Burlington, ON,
Canada), transferred onto a 0.45um nitrocellulose membrane (Pierce nitrocellulose membrane, Thermo
Scientific, Rockford, IL), stained with Ponceau S (Boston BioProducts, Ashland, MA), and imaged.
After a 5-minute incubation period, the Ponceau S was rinsed in deionized water, followed by trisbuffered saline with 0.05% Tween-20 (TBST) before blocking with 5% non-fat dry milk (NFDM) in
50ml TBST for one hour at room temperature. After blocking, the BAT membrane was probed with a
primary (1:500, rabbit anti-mouse IgG Abcam, Cambridge, MA, USA) antibody diluted in 5% NFDM in
TBST at 4°C for 24 hours by gentle rocking and a secondary (1:1000, goat anti-rabbit IgG HRPconjugated, #p0217, Dako) antibody for 1 hour at room temperature diluted in TBST. Muscle GA
membrane was probed with a primary (1∶500, rabbit anti-mouse IgG, ThermoFisher Scientific Rockford,
IL, USA) antibody diluted in 5% NFDM in TBST at 4°C for 24 hours by gentle rocking and a secondary
(1:5000, goat anti-rabbit IgG HRP-conjugated, #32460, ThermoFisher Scientific, Rockford, IL)
antibody for 1 hour at room temperature diluted in TBST. Chemiluminescent detection (Pierce ECL,
Thermo Scientific, Rockford, IL) was carried out and digitally imaged (G∶BOX Gel imager, Syngene,
Cambridge, UK) using Genesnap software (Ver. 7.01, Syngene, Cambridge, UK). Protein expression
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levels were quantified using NIH ImageJ Software (v1.62) and represented as optical density in arbitrary
units (AU). Protein of interest area was normalized to total protein obtained from Ponceau S staining.
Polymerase Chain Reaction (PCR)
Hypothalamus samples were homogenized (Bead Mill 4, #15-340-164, Thermo Scientific,
Waltham, MA, USA) using QIAzol Lysis Reagent (QIAGEN). Briefly, RNA was extracted from
hypothalamus tissues using QIAzol Lysis Reagent (QIAGEN) and cDNA was generated using identical
amounts of RNA (25ul) from each hypothalamus sample (44ng/ul) in a QuantiTect Reverse
Transcription Kit (QIAGEN). Real-time PCR measurement of individual cDNA (44ng) were made
using RT² SYBR Green Mastermix (QIAGEN), RNase-free water, RT² qPCR Primer Assay (1uL), and
cDNA synthesis reaction (1uL) per sample were combined. Samples (25uL) were then placed in the
Rotor-Gene Q real-time cycler (QIAGEN). Cycling conditions for the Rotor-Gene consisted of
activating HotStart DNA Taq Polymerase (1 cycle, 10 min, 95°C) and performing florescence data
collection (40 cycles, 15s at 95°C, 30s at 60°C). The threshold cycle (Ct) was calculated for each well
and fold change relative to β-actin was reported. POMC (QIAGEN, RefSeq no. NM_008895.4), NPY
(QIAGEN, RefSeq no. NM_023456.2), and β-Actin (Cell Signaling Technology, 1:2000, #3700) RT²
qPCR primers were used.
Metabolic Monitoring
Animals were monitored for three days (singly housed) prior to the exposures and during the last
month of exposure (48 hours post last exposure) in a Comprehensive Lab Animal Monitoring System
(Oxymax CLAMS, Columbus Instruments). This non-invasive procedure measured basal metabolism,
cage movement, sleep patterns, and food monitoring, more specifically, measuring maximal oxygen
consumption (VO2), carbon dioxide production (VCO2), respiratory exchange ratio (RER), heat, sleep
%, and activity. Metabolic heat was calculated as: Heat = (3.815+1.232*RER)*VO2. Animals were
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individually housed for 3 days, receiving no exposure for the duration of the experiment and provided
food and water ad libitum.
Statistical Analysis
All data are presented as ± SEM. Statistical analyses were performed using Statview Statistical
Software package (version 5.0.01; SAS Institute, Inc., Cary, NC). For examining body mass, food
intake, body fat, and free fat mass, a repeated measures ANOVA (rANOVA) was used. An ANOVA
was used when comparing treatment groups for leptin, GLP-1, UCP-1, UCP-3, NPY, POMC, and
overall food intake. Where a main effect was observed, post hoc testing was performed using student’s t
tests.
RESULTS
Body Mass, Weight Gain, and Body Composition
All groups had similar body masses during the first month, however, E-cig and control mice had
a significantly higher body mass between months 2-7 compared to 3R4F mice (p<0.05, Figure 1A). At
month 8, E-cig mice had a significantly higher body mass than 3R4F mice (+10%; p<0.05, respectively,
Figure 1A), but not compared to control mice. At month 8, E-cig mice had gained significantly more
weight than 3R4F mice (+32%; p<0.01, respectively, Figure 1B), while control mice tended to gain
more weight than 3R4F mice (+23%), although this difference did not reach statistical significance
(p=0.056). No statistical significance was found between E-cig and control body mass or weight gain.
All groups mice had similar FFM and fat mass at prior to exposure. Mean FFM was significantly
reduced in 3R4F mice compared to E-cig and control mice (-6% and -5%; p<0.01, respectively, Table 1)
throughout the study. Similarly, mean EchoMRI fat mass was significantly reduced in 3R4F mice
compared to E-cig and control mice (-26% and -24%; p<0.05, respectively, Table 1) throughout the
study. E-cig and control mice had an elevated FFM at month 2 compared to 3R4F mice, and E-cig mice
had an elevated FFM at months 5 and 8 (p<0.05, Figure 1C) compared to 3R4F mice. E-cig and control
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mice had elevated fat mass at months 2 and 5 compared to 3R4F mice, but no difference at month 8
(Figure 1D). No statistical significance was found between E-cig and control FFM or fat mass.
3R4F mice experienced a significant reduction in BAT mass compared to control mice (-22%;
respectively, p<0.05, Figure 2A), but not compared to E-cig mice (-13%). There were no differences in
RpWAT or GnWAT weights between groups.
Food Intake and Appetite Regulating Hormones
E-cig mice consumed significantly more kcals during the total 15-day food intake measurement
trials (3 day averages) compared to 3R4F and control (50.7±2.3 vs. 42.8±0.8 and 45.2±1.0g, p<0.01,
respectively, Figure 3A). 3R4F mice consumed significantly less kcals than E-cig and control mice at
week 3, however, there were no significant differences between E-cig, 3R4F, and control kcal
consumption during the individual 3-day feeding trials at weeks 7, 19, 23, and 29 (Figure 3B). Group
food intake (Figure 3C) during the final month of exposures tended to be higher in E-cig compared to
3R4F mice, but did not reach statistical significance (p=0.13). Hypothalamic NPY and POMC mRNA
expression was unaltered between groups (Figure 4A&B). Serum leptin and total GLP-1 concentrations
were not different between groups (Figure 4C&D).
Basal Metabolism and Uncoupling Proteins
E-cig mice did not show significant differences in UCP-3 expression compared to either control
or 3R4F mice, however, control mice had elevated UCP-3 muscle expression (p<0.05) compared to
3R4F mice by western blot analysis (Figure 5A&B). E-cig mice had significantly higher UCP-1
expression in BAT compared to 3R4F mice (p<0.05), however, remained unchanged compared to
control mice (Figure 5C&D).
Heat production (kcal/hr) was significantly higher in E-cig mice by 15% and 16% during the
light-phase compared to 3R4F and control groups, respectively (p<0.01, Figure 6A). Dark-phase heat
production was not significant between groups (Figure 6B). Cage activity and movement was not
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different between groups during the day or night (Figure 6D,E,F). Total sleep was not significantly
difference between groups (Figure 6G,H,I).
Light-phase oxygen consumption (VO2) was significantly higher in E-cig (16%) and 3R4F
(12%) exposed mice compared to control (p<0.05, Figure 7A). Dark-phase VO2 consumption was not
different among groups (p>0.05, Figure 7B). Light-phase carbon dioxide production (VCO2) was
significantly higher in E-cig mice (17%, p<0.05, Figure7D), and trended towards significance in 3R4F
exposed mice (p=0.06) compared to control mice. Dark-phase VCO2 was not different among groups
(p>0.05, Figure 7E). Respiratory exchange ratio (RER) was not different among groups during either the
light- or dark-phase (Figure 7G,H).
Nicotine Absorption
Urine cotinine values were not significantly different between 3R4F and E-cig mice, however,
3R4F cotinine levels were trending towards significance (p=0.070, Table 1) compared to E-cigs.
Cotinine levels in control mice were undetectable.

DISCUSSION
The main findings of this study were that E-cig vapor exposure induced hyperphagia and
increased heat expenditure without inducing weight gain in this rodent model. These data suggest that,
like traditional cigarettes, basal metabolism is increased, however, E-cig exposure increases food intake
instead of producing an expected anorectic effect.
Effect of E-Cig Vapor on Body Mass and Body Composition
E-cig exposed mice did not differ in body weight after the 8-month exposure compared to
control mice, likewise, body fat and FFM were also unchanged (Table 1). At the time of sacrifice,
GnWAT, RpWAT, and BAT masses were similar between the two groups (Table 1). Moreover, body fat
and FFM EchoMRI measurements indicated similar fat and lean tissue growth in each group (Figure
1C&D). Traditional smoke exposure is known to increase lipolysis and decrease body weight (Tweed et
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al. 2012), however, through this study, we have discovered that chronic E-cig vapor exposure does not
have similar anorectic effects as traditional cigarettes. In a similar E-cig exposure study, rats injected
I.P. with e-liquid containing nicotine significantly decreased body mass, while e-liquid (0% nicotine) did
not alter body mass (El Golli et al. 2016). This finding demonstrates that nicotine is the major
component for weight loss in an E-cig model. The discrepancy for lack of weight loss in our E-cig mice
could be due to inadequate nicotine absorption delivered from E-cig vapor compared to I.P. injections,
exhibited by a trend for less urine cotinine levels compared to 3R4F mice (Table 1). Indeed, Farsalinos
et al. (2014) determined plasma nicotine levels are 185% higher from smoking one traditional cigarette
compared to E-cig vapor. Regardless, these data agree with Ponzoni et al. (2015) and Phillips et al.
(2015), that E-cig vapor (containing nicotine) does not alter body mass in mice following 2-months and
8-months of exposure, respectively. Collectively, these data suggest chronic exposure to E-cig vapor,
unlike traditional cigarettes, do not elicit weight loss, lipolysis, or muscular atrophy.
Effect of E-Cig Vapor on Food Intake and Energy Metabolism
E-cig exposed mice displayed increased heat production (Figure 6A), without a concurrent
decrease in body mass (Figure 1A) compared to control mice. However, E-cig exposed mice also
consumed significantly more kcals than control mice (Figure 3A). Together, these data suggest an
alteration in basal metabolism and appetite regulation in E-cig mice. To test this, we measured UCP-1,
UCP-3, NPY, POMC, leptin, and total GLP-1 under basal, fasted conditions after the 8-month exposure,
and VO2, VCO2, and RER during month 0 and 7. Within the brain, leptin acts on OB-R-expressing
neurons and interacts with a multifaceted neural network to regulate long-tern energy balance. Leptin,
released from white adipose tissue in response to a meal, inhibits orexigenic neurons that synthesize
NPY, while stimulating anorexigenic neurons that synthesize POMC, resulting in anorexigenic effects
and decreased food intake (Erickson et al. 1996). Circulating serum leptin levels are directly correlated
to white adipose mass, thereby reflecting long term energy storage (Park and Ahima 2015). Similarly,
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GLP-1 is a known potent appetite suppressant and is secreted in response to nutrient intake (Brubaker
and Anini 2003). Both serum leptin and GLP-1 concentrations were similar in E-cig exposed mice
compared to controls and 3R4F mice (Figure 4C&D). As WAT weights were similar and all mice
underwent an 8-hour fast prior to euthanasia, these results were not surprising. It was found that nicotine
administration reduces food intake and body mass through a leptin-independent pathway (Sanigorski et
al. 2002), as both lean and obese animals experienced significant weight reductions, while plasma leptin
levels dropped in the lean animals only.
As E-cig exposed mice displayed hyperphagia over the 8-month exposure, we measured NPY
and POMC mRNA expression, two key appetite-regulating cell populations within the arcuate nucleus
(ARC) of the hypothalamus. Both NPY and POMC mRNA expression were unaltered in E-cig and
3R4F mice compared to control mice (Figure 4A&B). Leptin binding to OB-R-expressing neurons
within the hypothalamus initiates the cascade of synthesizing POMC while inhibiting NPY, so without
elevated serum leptin levels, a null effect on POMC and NPY mRNA was expected. Future studies
should measure activation of neurons in response to E-cig exposure. While we did not see any
significant differences, nicotine has been shown to excite both hypothalamic NPY and POMC neurons
through binding to α7nAChRs on the neurons (Huang et al. 2011), with a greater depolarization and
spike frequency response from POMC neurons, eliciting a potential mechanism through which nicotine
may suppress appetite (Huang et al. 2011). Future studies should evaluate the spike frequencies and
depolarization values between NPY and POMC following E-cig exposure. Moreover, future studies
should examine the effects of E-cig vapor on POMC neurons and the melanocortin system, specifically,
α-MSH, AgRP, and MC4R expression. Moreover, the co-expressed NPY/AgRP and POMC/CART cell
populations, as well as reward centers of the brain should be examined to extrapolate any motivational
reward of E-cig use. As NPY expression is significantly increased from a high-fat chow diet, studying a
smoke cessation model and switching to E-cig use would be extremely beneficial to parse out the
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appetite regulatory mechanisms involved in E-cig use. Other possible neural circuits (reward-based
mechanisms) and satiety factors (CCK, PYY, insulin, and gut distention) may also be a factor in E-cig
exposure and should be examined in future studies.
This is the first study to report hyperphagia in response to chronic E-cig vapor exposure. E-cig
exposure has been reported to significantly increase appetite rating scores by 14% in humans (Cravo et
al. 2016) and decrease food intake in mice (El Golli et al. 2016) injected with e-liquid. Interestingly,
mice injected with e-liquid alone (0% nicotine) consumed the same amount of kcals as controls,
however, mice injected with e-liquid (0.5mg nicotine/kg/day) consumed significantly less food than
control animals (El Golli et al. 2016). That study, unlike ours, administered e-liquid intraperitoneally
instead of vaporizing the e-liquid. Nicotine pharmacokinetics could be significantly different between
I.P. injections and vapor exposure models. Previous studies reporting reduced nicotine absorption from
E-cig (Farsalinos et al. 2014a, Allen et al. 2016) compared to cigarette smoke may result in a limited
lipolytic and adrenergic effect elicited by E-cig use. One explanation for the limited anorectic results
from E-cig exposure are due to urine cotinine levels. Urine cotinine values tended to be higher in 3R4F
mice compared to E-cig (p=0.070, Table 1). E-liquid nicotine content was externally verified (University
of Virginia) and contained the listed amount of nicotine (18mg/ml).
Effect of E-Cig Vapor on Energy Expenditure
A novel finding of this study was that E-cig exposure increased heat production (kcal/h), VO2,
and VCO2, resulting in higher basal metabolism during the day (period of least activity in normal mice),
but not at night (period of greatest cage activity, Figure 6B). This suggests chronic E-cig use increases
basal metabolic activity without altering cage activity or metabolism when mice are most active. An
increased basal metabolism explains the lack of weight gain in the E-cig mice in the face of an increased
caloric intake.
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To measure basal metabolism and a possible mechanism for heat production, white adipose
UCP-1 and gastrocnemius muscle UCP-3 were examined. UCP-1 causes leakage of protons and a
decreased efficiency of the mitochondrial electron transport chain (respiratory chain), resulting in heat
production (Zoli and Picciotto 2012). Nicotine, like caffeine, is a stimulant and acts to suppress appetite,
induce thermogenesis, and reduce weight. Cigarette smoking and nicotine have been shown to increase
basal metabolic rate (BMR) by releasing catecholamines, epinephrine and norepinephrine, which
increase thermogenesis (Tweed et al. 2012). Light-phase VO2 was significantly higher in E-cig and
3R4F mice compared to controls (Figure 7A) but not during dark-phase, suggesting an increased basal
metabolic rate and greater energy expenditure during the period of a rodent’s dormant period. Similarly,
light-phase VCO2 was significantly higher in E-cig mice (Figure 7D), and trended towards significance
in 3R4F exposed mice compared to controls. As CO2 is a marker for cellular metabolism, an elevated
level suggests an increased metabolism in the E-cig mice.
In contrast to previous studies (Chen et al. 2008, Sanigorski et al. 2002), 3R4F mice did not
significantly reduce their food intake, even while decreasing their body mass and in the face of reduced
UCP-1 and UCP-3 expression, suggesting a mechanism of energy preservation and decreased
thermogenesis. Our testing of food intake (15 days out of 240 days) provided only a snapshot of total
caloric intake, thus 3R4F mice may have consumed significantly fewer calories, resulting in decreased
UCP-1 and UCP-3 expression, as fasting and chronic food deprivation has been reported to significantly
decrease BAT UCP-1 expression to preserve energy and decrease thermogenesis (Champigny and
Ricquier 1990).
To date, this is the first study to measure uncoupling proteins and basal metabolism in an E-cig
model. Interestingly, Phillips et al (2015) reported significantly higher body masses in a similar E-cig
exposure paradigm model following 8-months of exposure, without a change in food intake. Without
examining energy metabolism in these mice, it can be extrapolated that those mice had a significantly
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reduced basal metabolism, which resulted in a higher body mass. Contrary to our study, we report
increased heat expenditure which may influence basal metabolism. Future studies examining the causal
mechanism between metabolism, food intake, and body mass are needed to parse out these differences.
Interpretation and significance
Cigarette smoking has been shown to increase thermogenesis and decrease energy intake and
body mass, while smoking cessation has been shown to significantly increase weight gain. Studies have
investigated the use of E-cigs as a smoking cessation tool (Cravo et al. 2016, Caponnetto et al. 2013,
Dawkins et al. 2012, Russo et al. 2016) and have reported an elevated body mass at 12 and 24 weeks
after smoking cessation and while using E-cigs. Our study evaluated various metabolic factors in
response to chronic E-cig vapor exposure, and while we did not see significant results for body mass, we
report an increased food intake which may contribute to weight gain following smoke cessation.
Our data support the notion that E-cigs do not alter weight status, however this remains untested
as a smoking cessation model and in a human population. The physiological responses to smoking
cessation (weight gain and increased appetite) may be exacerbated by switching to an alternative
nicotine delivery device, such as an E-cig. The mechanism underlying hyperphagia remains unknown, as
none of our appetite-regulating hormones and peptides showed any difference, nevertheless we have
observed that E-cig mice increase food intake due to chronic exposure.
It is well accepted that smoking and nicotine cause an anorectic effect, reducing body mass and
food intake, while increasing thermogenesis and lipolysis. Added flavors have been shown to induce
appetite, but the combination of these two inputs are unknown. This study shows that long-term
exposure to a sweetened flavor (cappuccino) and nicotine prevents the anorectic effects that smoking
and nicotine alone induce. Similar weight gain indicates that, unlike traditional cigarettes, E-cig vapor
does not induce an anorectic state and a negative energy balance which would lead to reduced weight,
rather, E-cig mice exhibited a hyperphagic response by consuming significantly more kcals than control
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mice. Increased food intake without increased body mass is very illogical. With an increased food
intake, an increased BMR provides a solid mechanism for heat dissipation that would result in an equal
energy balance and no weight gain/loss. Thus, propose that this similar weight gain pattern in the face of
hyperphagia is due to an increased basal metabolism. These data could also suggest a novel mechanism
for hyperphagia and BMR from chronic E-cig use with a sweet-flavored e-liquid. As this rodent model
produced promising preliminary results, future studies should examine the effects of E-cig vapor on
body mass and appetite regulation in humans.
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Table 1
Control
n=13

E-cig
n=11

3R4F
n=13

Body Mass (g)
Initial
19.7±0.3
19.6±0.2
19.8±0.3
Final
28.9±0.7
29.8±1.0#
27.1±0.7
Weight Gain (g)
9.3±0.5
10.2±0.9#
7.4±0.6
FFM (g)
Initial
15.8±0.2
15.5±0.4
15.1±0.3
Final
19.5±0.3
19.9±0.2#
18.7±0.2
Mean
18.0±0.2
18.2±0.2#
17.0±0.2*
Body Fat Mass (g)
Initial
1.7±0.1
1.9±0.3
1.6±0.1
Final
5.9±0.6
5.9±0.7
4.7±0.5
Mean
3.8±0.3
3.9±0.3#
3.0±0.2*
RpWAT (mg)
170±15
187±15
170±24
GnWAT (mg)
976±99
975±131
811±94
BAT (mg)
100±8
91±7
80±5*
Urine Cotinine
0.0±0
24.3±0.6
47.4±9.4
(ng/ml)
*p<0.05 compared to control group, #p<0.05 compared to 3R4F group.
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p-value

n.s.
p<0.05
p<0.05
n.s.
p<0.05
p<0.01
n.s.
n.s.
p<0.05
n.s.
n.s.
p<0.05
p=0.070
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Figure 1. Body mass, weight gain, FFM, and Fat Mass of control, E-cig, and 3R4F mice. Body mass
(A) was measured 2 times a week (n = 13 3R4F, n = 13 control, and n = 11 E-cig). Weight gain (B) of
animals were calculated as body mass at time of euthanasia minus initial body mass before exposure
initiation. Fat Mass (C) and FFM (D) analyzed via EchoMRI Body Composition Analyzer measuring
live body composition at month 0, 2, 5, and 8. Data presented as mean ± SEM. Repeated measures
ANOVA was used for body mass, FFM, and fat mass, while weight gain was analyzed by ANOVA and
Fisher’s Partial Least-Squares Difference (PLSD). Values are expressed as mean ± SEM. * p<0.05
different from control, # p<0.05 different from 3R4F. Chronic E-cig exposure had no effect on body
mass, total gain, FFM, or fat mass compared to controls, while 3R4F exposed mice experienced
significant body mass loss, and reduced weight gain, FFM and fat mass.
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Figure 2. Brown adipose tissue (BAT) weight, retroperitoneal white adipose tissue (RpWAT), and
gonadal white adipose tissue (GnWAT) weight in control, E-cig, and 3R4F mice. Tissue mass of
brown adipose tissue (BAT, A), retroperitoneal white adipose tissue (RpWAT, B), and gonadal white
adipose tissue (GnWAT, C) were measured at time of euthanasia after the 8-month exposure. N = 13
Control, n = 12 3R4F, n= 11 E-cig for all figures. Values are expressed as mean ± SEM and after an 8-hr
caloric fast. * p<0.05 different from control, # p<0.05 different from 3R4F. Chronic E-cig exposure had
no effect on BAT, RpWAT, and GnWAT, while 3R4F exposed mice displayed significantly less BAT
than control mice.
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Figure 3. Combined (15-day) food intake, food intake, and group food intake of control, E-cig, and
3R4F mice. Total food intake over 15 days (A) was calculated as total kcals consumed per treatment
group over the course of the 5 feeding experimental weekends. Average food intake (B, 3-day) was
measured at weeks 3, 7, 19, 23, and 29 from Friday-Monday during no exposures in individual housing
(n = 13 3R4F, n = 13 control, n = 12 E-cig). Kilocalories (kcals) were calculated as grams eaten x 3.1.
Values are expressed as mean ± SEM. Repeated measures ANOVA was used for food intake (B).
Weekly, group food intake (C) was measured during the last month of exposure and reported as g/week.
* p<0.05 different from control, # p<0.05 different from 3R4F. Chronic E-cig exposure significantly
increase total caloric intake over 15 days compared to control and 3R4F exposed mice. 3R4F mice
consumed significantly fewer kcals compared to E-cig and control mice at w3, but not during the
remaining weeks.

57

58

Figure 4. RT-PCR analysis of hypothalamic neuropeptide-Y (NPY) and pro-opiomelanocortin
(POMC), and serum concentration of glucagon-like peptide-1 (GLP-1) Total and leptin.
Neuropeptide-Y (NPY, A) and pro-opiomelanocortin (POMC, B) mRNA expression are relative to βactin mRNA (n = 8). Gene expression values are expressed as fold change relative to control mean
values (B-actin). Mean circulating serum GLP-1 Total (C, n = 12, 12, 11) and leptin (D, n = 12, 11, 13)
values as analyzed by ELISA kit. Leptin concentrations are expressed as ng/ml and GLP-1 Total are
expressed as picomolar (pM) on a standard log. Values are expressed as mean ± SEM and after an 8-hr
caloric fast. * p<0.05 different from control, # p<0.05 different from 3R4F. Chronic E-cig exposure had
no effect on POMC or NPY mRNA gene expression. Similarly, leptin and GLP-1 Total concentrations
were unchanged in E-cig mice compared to control animals.
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Figure 5. UCP1 and UCP3 protein expression in control, E-cig, and 3R4F mice. (A) Protein isolated
from gastrocnemius muscles of control (n=6), E-Cig (n=6), and 3R4F (n=6) mice under basal conditions
probed for UCP-3, shown at 34 kDa. Ponceau S stained membrane shows equally loaded total protein in
each lane. (B) Quantification of UCP-3 normalized to total protein. (C) Protein isolated from BAT of
control (n=8), E-cig (n=8), and 3R4F (n=8) mice under basal conditions probed for UCP-1, shown at 33
kDa. Ponceau S stained membrane shows equally loaded total protein in each lane. (D) Quantification of
UCP-3 normalized to total protein. Values are expressed as mean ± SEM. * p<0.05 different from
control, # p<0.05 different from 3R4F. Chronic E-cig exposure had no effect on UCP-1 or UCP3 protein
expression compared to control mice. 3R4F exposed mice experienced significant reductions in UCP-3
compared to control mice and UCP-1 compared to E-cig mice.
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Figure 6. Heat production, activity, and sleep during both light-phase and dark-phase periods in
control, E-cig, and 3R4F mice. Light-phase, dark-phase, and total heat production (A, B, C), activity
(D, E, F) and sleep percent (G, H, I) were measured in the CLAMS system. Metabolic heat was
calculated as: Heat = (3.815+1.232*RER)*VO2. Values are expressed as mean ± SEM. * p<0.05
different from control, # p<0.05 different from 3R4F. Chronic E-cig exposure significantly increased
light-phase heat production compared to control and 3R4F mice, but not during dark-phase. No
significance was found for activity or sleep percent among any group.
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Figure 7. VO2, VCO2, and RER during both light-phase and dark-phase periods in control, E-cig,
and 3R4F mice. Light-phase, dark-phase, and total VO2 (A, B, C), VCO2 (D, E, F) and RER (G, H, I)
were measured in the CLAMS system. Values are expressed as mean ± SEM. * p<0.05 different from
control, # p<0.05 different from 3R4F. Chronic E-cig exposure significantly increased light-phase VO2
and VCO2 production, but not at dark-phase. No significance was found for RER among groups.
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CHAPTER 4: SUMMARY AND DISCUSSION
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The principle finding of this work is that chronic E-cig exposure induces hyperphagia and
increases basal metabolic rate, total oxygen consumption, and carbon dioxide production, without
changing body mass in a rodent model. Following eight months of vapor exposure, E-cig mice displayed
increased body mass, food intake, heat production, and WAT UCP1 expression compared to 3R4F mice,
and increased food intake, heat production, VCO2, and VO2 compared to control mice. These data
suggest that, unlike traditional 3R4F cigarettes, chronic E-cig exposure blunts the anorectic and weight
loss effects from smoking and nicotine. Moreover, E-cig vapor increases caloric intake compared to
control mice, suggesting an appetite stimulating effect from the flavor, taste, or aroma perception
elicited from E-cig vapor.
4.1 Specific Aim 1: Body mass, body composition, and food intake
Specific Aim 1 was to determine the effects of long-term E-cig exposure on body mass, feeding
behavior, and body composition. It was hypothesized that chronic E-cig vapor would decrease
bodyweight, food intake, WAT, BAT, and LBM. To investigate this, we measured body mass 2x/wk, 3day food intake (Fri-Mon) at weeks 3, 7, 19, 23, and 29, WAT, and BAT post euthanasia, and body
composition (FFM and Fat Mass) with the EchoMRI Body Composition Analyzer at months 0, 2, 5, and
8. We found that E-cig mice gained weight similarly to control mice, however, gained significantly more
weight than 3R4F mice (Chapter 3, Figure 1B). Interestingly, both food intake (Chapter 3, Figure 3A)
and heat production (Chapter 3, Figure 6A) were significantly increased in E-cig mice compared to both
control and 3R4F mice. FFM, Fat Mass, WAT, and BAT were unchanged compared to control mice
(Chapter 3, Table 1), however, E-cig and control mice had significantly elevated mean FFM and fat
mass compared to 3R4F mice (Table 1), while month 8 fat mass was similar in all exposure groups and
FFM was significantly lower in 3R4F mice compared to E-cig mice (Chapter 3, Figure 1C).
Similar weight gain following eight months of chronic E-cig exposure compared to controls
indicate that, unlike traditional cigarette smoke, E-cig vapor does not induce an anorectic state and a
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negative energy balance, but rather, an orexigenic state exhibited by hyperphagia, without inducing
obesity. A combination of increased food intake and increased heat production, may provide a
mechanism for heat dissipation that would result in an equal energy balance. We propose that this
similar weight gain pattern in the face of hyperphagia is due to an increased metabolic rate. These data
could also suggest a novel mechanism for increasing food intake and BMR from chronic E-cig use.
Chronic (7-month, 4hr/d, 5d/wk, 30 min breaks) E-cig exposure has been reported to
significantly increase body weight compared to control and 3R4F exposed female C57BL/6 mice
(Phillips et al. 2015), without affecting food intake. Interestingly, these results were found in the face of
similar test atmosphere nicotine content (34ug/L) and serum nicotine and cotinine values as 3R4F mice.
This indicates that content of e-liquid may increase body weight independent of nicotine levels, and
through an unrelated food intake mechanism, possibly uncoupling proteins and thermogenesis.
However, a similar study (8-month, 3hr/d, 5d/wk, 30 min breaks) exposing female apolipoprotein Edeficient (Apoe -/-) transgenic mice, a model for smoking-related atherosclerosis, exhibited no effect on
body weight in the E-cig group, while the 3R4F group lost body weight. Much like the aforementioned
study, both 3R4F and E-cig mice had similar serum nicotine and cotinine levels. Urine cotinine values
tended to be higher in 3R4F mice compared to E-cig mice (p=0.070, Chapter 3, Table 1) in this study.
Control mice serum contained virtually no cotinine levels. The lack of weight loss and suppressed
appetite may be driven by a decreased nicotine absorption from E-cigs. E-liquid nicotine content was
externally verified (University of Virginia) and contained the listed amount of nicotine (18mg/ml).
Our results agree with Phillips et. al. (2016), Kogel et. al. (2014), and Cannazza et. al. (2015),
whom exposed mice to E-cig, 3R4F smoke, or filtered air for 7 months, 8 months, and 7 weeks,
respectively, and found significant weight loss in the 3R4F mice and no effect on E-cig mice body mass.
However, our findings of hyperphagia are the first to be reported in any rodent or human E-cig study.
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Adding to the controversy between the effect of nicotine on bodyweight, McGrath-Morrow et al.
(2015) exposed neonatal C57BL/6 mice to e-liquid with either 1.5% nicotine and propylene glycol or
0% nicotine in propylene glycol for 10 days and both groups of mice lost weight (13.3% and 11.5%,
respectively). Nicotine alone did not account for weight loss; however, infants and neonates have a
higher capacity to absorb nicotine and E-cig contaminants through the skin due to an increased surface
area relative to body weight and an immature epidermal barrier. This could contribute to weight
reductions in both nicotine and non-nicotine exposed mice. Counter to this study, it was found that I.P.
injections of nicotine (0.5mg/kg/day) and e-liquid (0.5mg nicotine/kg/day) induce significant weight
loss compared to I.P. injections of e-liquid (0% nicotine) and control male rats (El Golli et al. 2016).
Similarly, 0% e-liquid and control mice ate significantly more kcals than the nicotine-containing e-liquid
and nicotine groups. This indicates that nicotine directly inhibited food intake and contributed to weight
loss. The use of neonatal mice and male rats may have elicited weight-reducing effects from E-cig usage
due to immature epithelial tissue and sexual dimorphism between male and female rodents.
E-cig mice gained significantly more body weight, FMM, and fat mass, while increasing food
intake and heat production compared to 3R4F mice. Group food intake during the final month of
exposures tended to be higher in E-cig compared to 3R4F mice, but did not reach statistical significance
(p=0.13, Figure 3C). Cigarette smoke is known to inhibit appetite, increase energy expenditure, and
reduce bodyweight via nicotine’s anorectic effects (Zoli and Picciotto 2012). Both E-cig and 3R4F
exposure delivered nicotine, however, the artificial sweeteners and added flavors in the cappuccinoflavored e-liquid may have blunted nicotine’s anorectic effects. Nicotine is a weak primary reinforcer
and acts to enhance responding to reinforcing stimuli. Added flavors in e-liquid could potentially act as
reinforcers, which in conjunction with nicotine, may increase a user’s drive to smoke E-cigs. Nicotine
administration has been shown to increase sucrose seeking behavior as a reward mechanism in male rats
(Grimm et al. 2012). Sucrose, like artificial sweeteners and flavoring chemicals, is reinforcing due to its
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tastant (sweetness) properties. However, unlike artificial sweeteners, sucrose is also reinforcing due to
its source of calories. Literature surrounding which of these two sucrose-reinforcing properties
predominates remains unclear, however, if sweetness reinforcement is enhanced by nicotine, sweet eliquid products may increase high-sugar, sucrose-dense foods. In a study investigating whether nicotine
enhances responding to sucrose and if palatable or caloric properties of sucrose drive this process in
male rats discovered that nicotine administration significantly enhanced the reinforcement value for
sucrose (120% increase) and saccharin (100%), however, not for chow food (50%) (Rupprecht et al.
2016). This discovery demonstrates that smoking and nicotine reinforces the drive for sweet and
calorically dense food, instead of a normal diet. The inclusion of added flavors in the E-cig may have
increased the reward mechanism for a normal diet more than the 3R4F exposed mice, resulting in an
increased food intake.
Growth hormone, a peptide hormone that stimulates growth, was significantly increased in 3R4F
compared to E-cig and control mice following 7-months of daily exposures (Phillips et al. 2015), yet
3R4F mice exhibited significant weight loss. E-cig mice significantly increased body weight without
increasing food intake or growth hormone secretion, indicating a separate mechanism for weight gain,
possibly decreased thermogenesis and energy expenditure. Unfortunately, thermogenic markers such as
UCP-1 and UCP-3 or heat production in CLAMS was not measured in that study.
4.2 Specific Aim 2: Appetite Regulation and Energy Metabolism
Specific Aim 2 was to determine the metabolic and molecular consequences on appetite
regulation pathways with long-term E-cig exposure. It was hypothesized that E-cig exposure would
decrease serum leptin (in correlation with adipose tissue), GLP-1, and hypothalamic NPY mRNA
expression, while increasing hypothalamic POMC mRNA expression, UCP-1 in BAT, and UCP3 in GA
muscle. Together, this would result in an anorectic, hypophagic, net negative energy balance
physiological response. To investigate this, we attempted to measure serum leptin and GLP-1
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concentrations with a commercially available enzyme-linked immunosorbent assay (ELISA) kit,
hypothalamic NPY and POMC mRNA with qPCR, and UCP-1 and UCP-3 by western blot. Among all
groups, no differences were observed for serum leptin and GLP-1 protein concentrations, or NPY and
POMC mRNA expression. E-cig mice had significantly higher UCP-1 expression than 3R4F mice, and
3R4F mice had significantly reduced UCP-3 compared to control mice.
Hypothalamic NPY and POMC mRNA expression was measured via PCR (Chapter 3, Figure
3AB) to assess neurons within the ARC that are critical for peripheral hormonal sensing to influence
appetite regulation. Peripheral signals, such as leptin and ghrelin, act directly on the ARC to influence
the release of these two neuropeptides, which ultimately influence appetite (Park and Ahima 2015).
Raised levels of ghrelin, suggesting a starvation state and inadequate energy stores, act to stimulate
NPY/AgRP expression so as to increase hunger and initiate feeding, while inhibiting POMC/CART
expression. Likewise, raised levels of insulin, such as after a meal and indicating a fed state, act to
increase expression of POMC/CART to terminate feeding, while decreasing expression of NPY/AgRP.
As the current study discovered a hyperphagic response due to E-cig vapor, it would be expected to
witness a rise in NPY mRNA, with a concurrent decrease in POMC mRNA. While we did not see any
significant differences, nicotine has been shown to excite both hypothalamic NPY and POMC neurons
and α7nAChRs on the neurons (Huang et al. 2011), with a greater depolarization and spike frequency
response from POMC neurons, eliciting a potential mechanism through which POMC may suppress
appetite (Huang et al. 2011). Future studies should evaluate the spike frequencies and depolarization
values between NPY and POMC following E-cig exposure. Moreover, other possible neural circuits
(reward-based mechanisms) and satiety factors (CCK, PYY, insulin, and gut distention) may also be a
factor in E-cig exposure and should be examined in future studies.
Leptin concentrations in serum collected at time of euthanasia were measured (Chapter 3, Figure
3D) via ELISA in attempt to determine differences in circulating levels. Circulating leptin levels are
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directly proportional to fat stores and reflect the status of long-term energy stores within an organism
(Park and Ahima 2015). As leptin can be specifically transported through the blood-brain-barrier (BBB)
and is likely not synthesized in the brain, intracerebral leptin levels usually reflect serum leptin levels
(Zoli and Picciotto 2012). A change in leptin concentration due to E-cig exposure could have several
implications. In regards to specific aim 1, changes in serum leptin concentrations may simply reflect
changes in white adipose tissue mass. However, regarding specific aim 2, to the best of our knowledge,
no one has examined the effect of nicotine and sweet aromatics on satiety hormones. Alterations in
leptin concentrations following nicotine or E-cig vapor may be secondary to nutrient intake and
fluctuating WAT mass. Proving this notion, it was found that nicotine exposure did not significantly
alter leptin mRNA in cultured adipocytes, or leptin release from adipocytes (Reseland et al. 2005). In
our mouse model, no differences were observed in circulating serum leptin levels between any of the
groups.
To date, only one published study has investigated the effects of E-cig vapor on serum leptin
concentrations (Phillips et al. 2015). This is the first study to investigate the effects of E-cig exposure on
multiple appetite regulating biomarkers to further elucidate the scientific understanding of appetite and
energy balance from E-cig exposure. Serum leptin levels in female 3R4F mice have been reported to be
significantly reduced compared to E-cig mice (Phillips et al. 2015), in correlation to reductions in
gonadal and retroperitoneal WAT. As most body weight studies are conducted using male animals, this
female model must be taken into consideration in light of the limitations. In the current study, gonadal
and retroperitoneal WAT masses were not significantly different amongst groups, similarly, leptin levels
were unaltered. A lack of change in serum leptin alteration would lead to a null effect on NPY and
POMC mRNA expression within the hypothalamus, as leptin binds to LepR to exert its effects directly
on these ARC subpopulations. As sweet aromas have been shown to increase feeding patterns and
appetite, a decrease in serum leptin would increase NPY and inhibit POMC expression. However, as
72

NPY, POMC, leptin, and GLP-1 levels were not altered in this study, other factors (other neural
systems) may be at play to influence appetite. To further investigate these findings, shorter-term
activation studies may elicit more pronounced effects. Moreover, leptin could be measured
intermittently throughout the study or secretion from white adipose tissue.
Serum GLP-1 concentration was also measured to investigate motivation (reward) to eat and the
hedonic value (pleasure) of food from chronic E-cig exposure (Chapter 3, Figure 3C). GLP-1, a known
potent appetite suppressant, is excreted in response to nutrient intake (Brubaker and Anini 2003) and
regulates body weight and food intake (Phillips et al. 2016, Turton et al. 1996). It also acts to decrease
mesolimbic dopamine signaling, which controls pleasure-directed food intake (Geloneze, de Lima and
Velloso 2017). In a 7-month study, serum GLP-1 tended to be elevated in E-cig mice compared to 3R4F
and control mice, but did not reach statistical significance (Phillips et al. 2015). This would have
resulted in a decreased hedonic value (pleasure) of food, decreased motivation (reward) to eat, and
decreased quantity and frequency of food consumption, yet food consumption was reported to be
unaltered and E-cig mice gained significantly more weight. The use of a sweet flavored e-liquid
(cappuccino) may have decreased the GLP-1 in this study relative to Phillps et al. (2015) which used
tobacco-flavored e-liquid, resulting in a slightly increased hedonic value for chow pellets, an increased
motivation to eat, increased meal frequency, and an overall increase in caloric intake.
Heat production via non-shivering thermogenesis is the main function of BAT and
norepinephrine is thought to be the main driver in BAT thermogenesis regulation (Cannon and
Nedergaard 2004). Nicotine, through central and peripheral binding to nAChRs, triggers the release of
both epinephrine and norepinephrine in response to an acute smoke exposure (Sala et al. 2008, Zhao et
al. 2007, Westfall and Watts 1964), thereby increasing activity of the sympathetic nervous system. BAT
UCP-1, a marker for non-shivering thermogenesis, was markedly reduced in 3R4F mice compared to Ecig mice, but not control mice. As nicotine is a known CNS stimulant and increases thermogenesis in
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BAT, the reduced UCP-1 expression in 3R4F mice may suggest energy expenditure preservation by
reducing thermogenesis. The marked elevation in UCP-1 expression in E-cig mice compared to 3R4F
mice could indicate a relatively elevated energy expenditure, which is evidenced by increased heat
production measured in the CLAMS and preservation of body weight. Likewise, muscle UCP-3,
important in mitochondrial fatty acid transport and basal metabolic rate, was significantly reduced in
3R4F mice compared to controls, suggesting preservation of energy expenditure and a reduced ability
for fatty acid utilization in skeletal muscle. However, both acute (Yoshida et al. 1994) and chronic (Arai
et al. 2001, Yoshida et al. 1999) nicotine administration and chronic smoke exposure (Chen et al. 2008)
have been reported to increase CNS sympathetic activity, catecholamine release, and BAT UCP-1
expression, which increases thermogenesis.
The lack of increased UCP-1 expression in the 3R4F mice may indicate inadequate smoke
exposure, however, the increased UCP-1 expression in E-cig mice compared to 3R4F mice, but similar
to controls, could indicate a relatively higher energy expenditure, possibly related to added flavors in
conjunction with vaporized nicotine. Light-phase VO2 was significantly higher in E-cig and 3R4F mice
compared to controls (Chapter 3, Figure 7 A&B) but not during dark-phase, suggesting an increased
basal metabolic rate and greater energy expenditure during the period of a rodent’s dormant period.
Similarly, light-phase VCO2 was significantly higher in E-cig mice (Chapter 3, Figure 7 D&E), and
trended towards significance in 3R4F exposed mice compared to controls. As CO2 is a marker for
cellular metabolism, an elevated level suggests an increased metabolism in the E-cig mice compared to
3R4F mice, which was consistent with the UCP-1 data. While activity was not significantly different
among groups (Chapter 3, Figure 6 D&E), the 3-day measurement window may be too little time to
conclude that activity was not an important factor in energy metabolism. Possible increased activity in
E-cig mice may also explain the similar body weight to control mice despite an increased caloric intake.
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Adrenergic control of BAT adipocytes is sexually dimorphic in the rat and it has been shown the
overfeeding in male rats significantly increases norepinephrine release and β3-adrenergic receptor
activation in BAT, however, overfeeding in female rats results in significant weight gain and decreased
thermogenesis activation (Rodriguez et al. 2001). As E-cig mice consumed significantly more kcals than
3R4F mice and had a significantly higher UCP-1 expression, indicating increased thermogenesis, this is
contradictory to the notion that overfeeding decreases thermogenesis activation. Future studies should
examine the effects of E-cig vapor exposure on both male and female animals to parse out the sexually
dimorphic differences between genders. As this is the first study investigating energy expenditure and
uncoupling proteins in an E-cig model, these results may lay the framework for future studies.
4.3 Future Work, Concerns, and Limitations
As E-cig use and obesity rates are increasing at an alarming rate, and the physiological effects
(i.e. appetite and energy balance) of E-cigs are virtually unknown, it is imperative to expand on the
current findings to gain more insight to the understanding of E-cig use on these factors. Cigarette
cessation has been attributed to a 14% rise in US obesity rates (Courtemanche et al. 2016) and
alternative nicotine therapies, such as E-cigs, are currently being used to help mitigate these effects.
However, with the current study, appetite and obesity rates may increase due to switching to E-cigs. A
possible solution may be to increase the nicotine dose in E-cigs to prevent the weight gain effects from
smoking cessation. To fully elucidate the effects of e-liquid on body mass and food intake, a study using
non-nicotine e-liquid would be able to answer the question if nicotine alone is driving these phenomena.
The melanocortin system, a key player in appetite regulation and food intake, is directly
stimulated by nicotine through POMC activation, which ultimately suppresses food intake (Huang et al.
2011, Mineur et al. 2011). Cigarette cessation is immediately followed by weight gain, which is
associated with a reduced activity of melanocortin-4 receptors within the hypothalamus, essentially
removing the brake from appetite control and resulting in increased food intake. Future studies should
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examine the effects of E-cig vapor on POMC neurons and the melanocortin system, specifically, α-MSH
protein expression. Moreover, the co-expressed NPY/AgRP and POMC/CART cell populations, as well
as reward centers of the brain should be examined to extrapolate any motivational reward of E-cig use.
As NPY expression is significantly increased from ingestion of a high-fat chow diet, studying a smoke
cessation model and switching to E-cig use would be extremely beneficial to parse out the appetite
regulatory mechanisms involved in E-cig use.
Future studies need to include an analysis of leptin receptor expression within the hypothalamus.
As leptin is the main anorexigenic peptide influencing appetite, it is imperative to understand possible
leptin resistance within the brain. Serum and urine cotinine should also be examined at structured
timepoints to determine levels of nicotine absorption, as well as particulate matter, carbon monoxide,
and environmental nicotine within the chamber. The inability to determine atmospheric and serum
nicotine levels is a major limitation of this study, yet, the smoke exposures were matched for time, so as
to provide similar smoke/vapor exposure.
Additionally, future studies using direct smoke/vapor exposure (via direct nose inhalation) will
increase the rate of nicotine absorption and mimic a more realistic/translational model. Likewise,
measuring food consumption throughout the study, instead of only on weekends (without exposure)
should be conducted to get a more accurate measurement of total caloric intake. While this study
showed a hyperphagic response in the E-cig group, this may be due to nicotine withdrawal or sweet
flavor withdrawal on the weekends. This pilot study employed the use of a group-housed smoking
chamber to deliver vapor, cigarette smoke, or filtered air. This excluded routes of administration other
than inhalation, such as ingestion and absorption as human smokers experience. E-cig users may have a
different phycological stimulus to the mouthfeel, flavor, and aroma perception from directly inhaling the
e-liquid, unlike the mice in this study.
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It would be interesting to repeat this present experiment on an OZR rat model, with leptin
deficiency, or in a pair-fed control design with control mice consuming identical calories as the E-cig
and 3R4F group to determine physiological differences without caloric intake contributing in the
equation. An obesogenic model, such as a diet-induced-obesity (DIO) rat or mouse model would be
interesting to expose to E-cig exposure, as nicotine has been shown to reverse the effects of DIO
(Seoane-Collazo et al. 2014). The added sweeteners in E-cigs may override nicotine’s anorectic effects,
resulting in the expected DIO from a high-fat diet. Most interesting, providing a high fat diet may
provide differing results, as sweet flavors and calorically dense foods increase the desire to consume
fat/sweet food, perhaps exposure to E-cig would increase food intake to an even greater extent. As
previously stated, numerous homeostatic circuits underlie food intake (Morton et al. 2014) and feeding
is regulated by pleasant aromas (hedonic) or reward-based sensations, which override homeostatic
controls when consuming energy dense foods, increasing desire to consume palatable foods (Lutter and
Nestler 2009). Sight and smell of palatable food increases dopamine release from the ventral tegmental
area (VTA), which contributes to the reward value of food (Morin et al. 2017), which when consuming
food, this pathway activation results in loss of control over intake of food (Stoeckel et al. 2008). If fed a
high-fat, palatable diet instead of standard chow, the E-cig exposure may increase food intake to an even
greater degree.
The current study design measured food intake at three distinct timepoints (weeks 3, 7, 19, 23,
and 29) over a three-day span (Friday-Monday, during no exposures) in mice individually caged. To
accurately calculate total caloric intake, future studies should measure food intake each week throughout
the study. Space restrictions and group-housing of mice made it difficult for the current study to measure
food intake on a weekly basis. As nicotine withdrawal over the weekends may produce differing food
intake, these data may be different throughout the weekly exposures. Moreover, mice were removed
from their group-housing during food intake measurements into individually housed cages. The effects
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of social isolation, depression, and anxiety from removal of littermates may have played a role in satiety
and total caloric intake. Proving this notion, both E-cig and control mice lost ≈2.5g of bodyweight
during the final week in CLAMS, while 3R4F mice did not significantly alter bodyweight. Finally, as
female mice have a more robust protection against weight loss from nicotine administration and smoke
exposure, future studies should examine the physiological effects of E-cig vapor in a male mouse/rat
model to parse out gender differences.
To date, the FDA has no regulations or restrictions placed on E-cig manufacturers to disclose
ingredient lists, product contents, or manufacturing specifications, therefore, the ingredients and nicotine
content are virtually unknown. We tested both e-liquids by mass spectrophotometry (University of
Virginia) and both samples contained 18.05 and 18.89mg/ml nicotine. One study reported more that
75% of tested e-liquid products contained significantly less nicotine levels (6% - 42% by concentration)
than listed on the label (Lisko et al. 2015). While some studies indicate E-cig refill liquid contain less
nicotine content than listed on the bottle (Lisko et al. 2015), the e-liquid in this study contained the listed
amount (18mg/ml).
Urine cotinine levels were measured for three consecutive hours post exposures at month 5
tended to be higher in 3R4F mice compared to E-cig mice (p=0.070) in our study. In an unpublished
intravital study done in our laboratory, C57BL-6 mice were exposed to the same e-liquid used in this
study for 5 minutes (30 sec on, 30 seconds off) with a direct first-hand nose exposure. Mice were
sacrificed 1.5 hours post exposure, which resulted serum cotinine values exceeding that of our 3R4F
mice (9.93ng/ml). Cotinine has an in-vivo half-life of 16-20 hours (Jarvis et al. 2001), while nicotine has
a half-life of 1-2 hours. Clearly, due to the short time interval between exposure and harvest, cotinine
values were significantly elevated as the half-life timepoint was not approached. Previous studies
indicate possible reasons for lower cotinine levels due to E-cig aerosol being absorbed in the oral
mucosa instead of lungs (Farsalinos et al. 2014a). Nicotine administered to oral mucosal should be
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swallowed, which leads to first-pass metabolism to the liver, reducing nicotine’s bioavailability. The
method of delivery, via liquid droplets of propylene glycol and glycerol, instead of cigarette particulate
matter may affect nicotine absorption as well.
4.4 Translational Significance
The U.S. Food and Drug Administration (FDA) have approved seven medications to aid in
tobacco cessation including: nicotine patches, gum, lozenges, nasal spray, inhaler, and two non-nicotine
pills (Zyban® and Chantix®). With the advent of E-cigs and the massive popularity arising in their use,
a better understanding of the mechanisms regulating appetite and energy balance with individuals who
use E-cigs will lead to an overall increased public knowledge and awareness as to their effects. With the
known anorectic effects of cigarette smoke, followed by smoke cessation weight gain and increased
appetite, the consequences of switching to E-cigs may lead to an exacerbated obesity epidemic. This
understanding will be important for public health smoke cessation therapeutic programs for individuals
currently using E-cigs as an intermediate step to quit smoking. E-cig use following complete cigarette
smoke cessation has been seen to significantly increase body weight after 12 and 24 weeks, however,
after 12 months of switching to an E-cig, weight gain was reversed and returned to baseline (Russo et al.
2016). A similar 12-month study evaluating the efficacy of E-cig use as a tobacco cessation tool found
no difference in body weight, however, only 11% of smokers were successful at quitting (Caponnetto et
al. 2013), which explains the lack of change in body weight. Moreover, sensorimotor components of Ecig use may play a significant role in reinforcement in human subjects rather than an animal model.
Perceived hunger ratings were significantly higher after just holding an E-cig compared to using it
(Dawkins et al. 2012). These results indicate that sensorimotor aspects of E-cig use, as well as
pharmacologic effects, play a significant role in dependence on nicotine and the feeling of smoking. In a
study evaluating physiological effects of cigarette cessation and switching to E-cig vapor in 306 human
subjects, 14.1% reported increased appetite, while only 1.0% of the continued cigarette smokers
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experienced increased appetite. With an alarming increase in the number of E-cig users, if these studies
and our results are confirmed, they may provide novel and fundamental findings to aid in the assistance
of smoke cessation and obesity prevention programs.
In 2011, almost 70% of current adult cigarette smokers wanted to quit smoking (USDHHS
2014). Moreover, current smokers were the most willing to try E-cigs (27.2%) compared to non-smokers
(2.5%) in a meta-analysis of 67 studies. Most surprising, over half of the study participants (52.6%)
perceived E-cigs as a healthier alternative to cigarette use, which influenced their willingness to try Ecigs in hope of cessation (Xu et al 2016). As smoking cessation increases body mass and using E-cigs
increases appetite, smokers may have less motivation to quit smoking in fear of gaining weight. By
sharing this knowledge about possible increased food intake due to E-cig use, the public can make
informed decisions based on smoking cessation and their overall health.
4.5 Conclusion
In conclusion, cigarette smoking causes appetite suppression and weight loss, and while E-cigs
are a popular smoking cessation tool, little is known about their metabolic and physiological effects. In
contrast to our first hypothesis (specific aim 1), E-cig vapor significantly increased caloric intake and
did not alter body mass, fat mass, or lean mass. Also in contrast with our second hypothesis (specific
aim 2), compared to controls, E-cig vapor does not significantly alter NPY or POMC mRNA, serum
leptin and GLP-1 concentrations, or BAT UCP-1 and GA UCP-3 concentrations. However, we
demonstrate a significant increase in heat production (kcal/hr), VCO2, and VO2, and cannot exclude the
possibility that increased caloric consumption offsets the increased basal metabolism to result in a
similar net weight gain, despite hyperphagia. Weight gain does not necessarily manifest due to increased
food consumption, but rather, complex and varied shifts in biochemical processes in energy metabolic
pathways that govern energy balance. We demonstrate here that chronic E-cig vapor induces
hyperphagia and increases basal metabolism without affecting body mass. Future studies should be
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conducted to verify and expand on these results as millions of Americans are currently using E-cig as a
smoking cessation device.
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